[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 156
1. Leblanc J, Kongkam P: Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report. Clin Med Oncol; 2009;3:59-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA) Diagnosis of Recurrent Anal Cancer After Chemoradiation and Negative Forceps Biopsies: A Case Report.
  • A 69-year-old woman with a history of uT2 N0 post-treated anal squamous cell cancer (SCC) presented for EUS for perianal pain.
  • A sigmoidoscopy revealed mild narrowing of the anal canal and an ulcerated friable mucosa in the same area.
  • While endoscopic biopsy of suspected anal recurrences is usually sufficient, histologic or cytologic confirmation are necessary, as radiation-induced changes are difficult to differentiate from tumor recurrence.
  • This case demonstrates that EUS-FNA is useful in surveillance of anal SCC when there is a high clinical suspicion of recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1996 Jul;91(7):1309-11 [8677984.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):906-12 [10201455.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):346-50 [12594671.001]
  • [Cites] Lancet Oncol. 2004 Mar;5(3):149-57 [15003197.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):940-7 [15329901.001]
  • [Cites] Cancer Invest. 2006 Aug-Sep;24(5):535-44 [16939964.001]
  • (PMID = 20689610.001).
  • [ISSN] 1177-9314
  • [Journal-full-title] Clinical medicine. Oncology
  • [ISO-abbreviation] Clin Med Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2872600
  •  go-up   go-down


2. Seya T, Tanaka N, Shinji S, Yokoi K, Oguro T, Oaki Y, Ishiwata T, Naito Z, Tajiri T: Squamous cell carcinoma arising from recurrent anal fistula. J Nippon Med Sch; 2007 Aug;74(4):319-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma arising from recurrent anal fistula.
  • Here, we report on a patient with squamous cell carcinoma (SCC) arising from recurrent anal fistula.
  • The patient was a 57-year-old woman who had 32-year history of having a recurrent perianal abscesses that ruptured spontaneously.
  • Six months before her admission to our hospital, anal pain developed.
  • Physical examination revealed three external fistulous openings at the two o'clock position, 2 cm from the anal verge.
  • Microscopic examination showed SCC arising from the anal fistula, which was accompanied by vessel invasion.
  • Histopathological examination revealed no remnant cancer tissue or lymph node metastasis.
  • Urological examination revealed urinary bladder cancer, and transurethral resection of the bladder tumor was performed.
  • Histopathological examination revealed transitional cell carcinoma of the urinary bladder.
  • Two years later, the patient died of metastatic urinary bladder cancer, without recurrence of the fistula cancer.
  • Because the patients mother had died of urinary bladder cancer and she herself had metachronous urinary bladder cancer in addition to fistula cancer, we investigated whether microsatellite instability (MSI) and chromosomal instability correlated with fistula cancer development.
  • Our patient had MSI and one of the smallest reported SCCs arising from recurrent anal fistulae.
  • [MeSH-major] Anus Neoplasms / etiology. Carcinoma, Squamous Cell / etiology. Rectal Fistula / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Female. Humans. Microsatellite Instability. Middle Aged. Neoplasms, Second Primary / pathology. Recurrence. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878704.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Sana S, Khan AU: Clinical trials in the management of anal cancer. Clin Colon Rectal Surg; 2009 May;22(2):115-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trials in the management of anal cancer.
  • Our understandings of anal canal cancer pathogenesis and treatment have undergone significant changes due to continuing research into its pathogenesis and the results of major clinical trials conducted over the past 20 years.
  • Anal canal cancer can be cured by combined modality chemoradiation therapy, a treatment that preserves continence and reserves abdominoperineal resection of the rectum and anal canal in patients with recurrent or residual disease after primary chemoradiotherapy.
  • This article aims to provide a summary of recently completed and ongoing clinical trials in the management of anal canal cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2550-7 [18427149.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):119-26 [18472366.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1994 Mar;8(3):283-95 [8031509.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3121-5 [8955657.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • (PMID = 20436836.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780239
  • [Keywords] NOTNLM ; Anal canal cancer / chemotherapy / radiation therapy
  •  go-up   go-down


Advertisement
4. Rouquie D, Lasser P, Castaing M, Boige V, Goéré D, Pignon JP, Ducreux M, Elias D, Pocard M: [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)]. J Chir (Paris); 2008 Jul-Aug;145(4):335-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete (R0) resection is the only valid prognostic factor in abdominoperineal resection for recurrent cancer of the anal canal (a consecutive series of 95 patients)].
  • [Transliterated title] Résection R0, seul facteur pronostique dans les amputations abdominopérinéales de rattrapage des cancers du canal anal (série consécutive de 95 patients).
  • INTRODUCTION: When radiation therapy fails to control cancer of the anal canal, the only therapeutic alternative is salvage abdomino-perineal resection (APR).
  • CONCLUSION: When anal cancer recurs after radiation therapy, a salvage APR is indicated.

  • Genetic Alliance. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18955923.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Christensen AF, Nyhuus B, Nielsen MB: Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer. Dis Colon Rectum; 2009 Mar;52(3):484-8
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interobserver and intraobserver variation of two-dimensional and three-dimensional anal endosonography in the evaluation of recurrent anal cancer.
  • PURPOSE: This study was designed to evaluate the interobserver and intraobserver agreement of two-dimensional (2-D) and three-dimensional (3-D) anal endosonography for the detection of local recurrence anal carcinoma.
  • METHODS: Thirty-six patients were treated for anal carcinoma, and seven had recurrent disease.
  • CONCLUSIONS: Three-dimensional endosonography proved to have significantly better interobserver and intraobserver agreement than 2-D endosonography concerning detection of recurrent anal cancer.
  • [MeSH-major] Anus Neoplasms / ultrasonography. Endosonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / ultrasonography. Female. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Observer Variation. Retrospective Studies

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19333050.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Commonly included in this group of cancers are Bowen's disease (intraepithelial squamous cell cancer), perianal Paget's disease (intraepithelial adenocarcinoma), invasive squamous cell cancer, basal cell cancer, and malignant melanoma.
  • Adjunct therapies have been utilized in more advanced or recurrent lesions, including radiotherapy, photodynamic therapy, and imiquimod.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down


7. Grigsby PW: FDG-PET/CT: new horizons in anal cancer. Gastroenterol Clin Biol; 2009 May;33(5):456-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT: new horizons in anal cancer.
  • Anal cancer is an uncommon tumor with an incidence of about one case per 100,000 in most countries.
  • Current treatment guidelines include fluorodeoxyglucose positron emission tomography integrated with computed tomography (FDG-PET/CT) as part of the standard pretreatment workup of patients diagnosed with anal cancer.
  • This imaging modality can also be used to evaluate sites of recurrent disease.
  • FDG-PET/CT is an imaging modality which greatly affects the management of patients with anal cancer.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19394179.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Troicki F, Pappas A, Noone R, Denittis A: Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. J Med Case Rep; 2010;4:67

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report.
  • INTRODUCTION: High-grade anal intraepithelial neoplasia, also referred to as anal squamous carcinoma in-situ, or Bowen's disease of the anus, make up less than 1% of all digestive system cancers in the United States.
  • The treatment of choice is surgical resection with anal mapping.
  • This can compromise the anal sphincter leading to leakage.
  • In this case report, we discuss the efficacy of radiation therapy as a modality to treat post-excisional recurrent Bowen's disease, which may prevent sphincter compromise, leading to improved quality of life.
  • CASE PRESENTATION: An 84-year-old Caucasian woman presented with post-excisional persistent/recurrent squamous cell carcinoma in-situ.
  • The initial lesion measured 3 cm in diameter on the right lateral side of the anal margin.
  • A standard surgery consisting of wide local excision with anal mapping was performed.
  • Our patient recurred with a 1.2 x 0.8 cm lesion on the left anal verge extending to the anal canal.
  • A biopsy along with mapping was done, and 2 of the 17 mapping specimens were positive for carcinoma in-situ, one in the anal canal.
  • Due to the location of the positive anal mapping, and in order to prevent sphincter compromise on re-excision, our patient was offered definitive radiation therapy.
  • Two years after radiation therapy, our patient showed no signs of recurrent disease and had good sphincter control.
  • CONCLUSION: Although the main treatment modality for treating persistent/recurrent Bowen's disease is surgery, an alternative approach using external beam radiation for CIS may be enough to provide a cure for some patients with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Australas J Dermatol. 2006 May;47(2):120-3 [16637809.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S25-33 [15753009.001]
  • [Cites] Swiss Med Wkly. 2003 Jun 28;133(25-26):353-9 [12947531.001]
  • [Cites] Br J Surg. 1997 May;84(5):675-8 [9171763.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Urol Clin North Am. 1992 Feb;19(1):83-91 [1310549.001]
  • [Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]
  • (PMID = 20181236.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2841077
  •  go-up   go-down


9. Christensen AF, Nielsen MB, Svendsen LB, Engelholm SA: Three-dimensional anal endosonography may improve detection of recurrent anal cancer. Dis Colon Rectum; 2006 Oct;49(10):1527-32
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional anal endosonography may improve detection of recurrent anal cancer.
  • PURPOSE: In our center since 2001, follow-up examination has included three-dimensional endosonography in all patients with suspicion of local recurrence of anal cancer.
  • METHODS: This prospective study included 38 consecutive patients who have had anal carcinoma and were investigated using three-dimensional endosonography in combination with anoscopy and digital rectal examination at Rigshospitalet from July 2001 to January 2005 under suspicion of local recurrence.
  • CONCLUSIONS: This study indicates that three-dimensional endosonography surpasses two-dimensional endosonography in the evaluation of patients with suspicion of local recurrence of anal cancer especially in combination with anoscopy and digital rectal examination.
  • [MeSH-major] Anal Canal / ultrasonography. Anus Neoplasms / ultrasonography. Endosonography / methods. Imaging, Three-Dimensional. Neoplasm Recurrence, Local / ultrasonography

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988854.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Rakoto-Ratsimba HN, Rakototiana AF, Rakotosamimanana J, Ranaivozanany A: [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case]. Ann Chir; 2006 Nov;131(9):564-6
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal adenocarcinoma revealed by a fistula-in-ano. Report of a case].
  • [Transliterated title] Fistule périanale révélatrice d'un adénocarcinome du canal anal. A propos d'une observation.
  • Anal adenocarcinoma revealed by a fistula-in-ano occurs rarely.
  • Recurrent or non recurrent fistula-in-ano requires multiple biopsies for pathology analysis in order to screen a related cancer.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Anus Neoplasms / complications. Anus Neoplasms / diagnosis. Rectal Fistula / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712770.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


11. Patel CB, Ramos-Valadez DI, Haas EM: Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations. Int J Med Robot; 2010 Dec;6(4):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted laparoscopic abdominoperineal resection for anal cancer: feasibility and technical considerations.
  • BACKGROUND: Robotic-assisted laparoscopic surgery is an emerging technology that may prove advantageous for complex colorectal procedures involving the irradiated pelvis, such as abdominoperineal resection for recurrent anal cancer.
  • METHODS: Over a 6 month period, five abdominoperineal resections were performed using the da Vinci® robot for recurrent anal cancer in patients initially treated with definitive chemoradiation therapy.
  • CONCLUSION: Robotic-assisted laparoscopic surgery for anal cancer was found to be a safe and feasible procedure.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Laparoscopy / methods. Perineum / surgery. Robotics / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 20827795.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Ferenschild FT, Vermaas M, Hofer SO, Verhoef C, Eggermont AM, de Wilt JH: Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer. World J Surg; 2005 Nov;29(11):1452-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection and perineal wound healing in local recurrent or persistent anal cancer.
  • The primary treatment for anal cancer is chemoradiation (CRT).
  • A major problem of surgery in the anal area is poor healing of the perineal wound.
  • Between 1985 and 2000, 129 patients treated for anal cancer were retrospectively reviewed.
  • In the present study salvage APR in recurrent or persistent anal cancer results in good local control and 5-year overall survival of 30%.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Salvage Therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222445.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Schiller DE, Cummings BJ, Rai S, Le LW, Last L, Davey P, Easson A, Smith AJ, Swallow CJ: Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol; 2007 Oct;14(10):2780-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.
  • BACKGROUND: For patients with anal canal cancer who fail combined modality treatment (CMT), salvage surgery (SS) offers the potential for long term survival.
  • METHODS: We identified 60 patients with persistent or recurrent anal cancer who had undergone SS; 20 were excluded.
  • CONCLUSION: SS for anal canal cancer was associated with significant morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / pathology. Anal Canal / surgery. Cancer Care Facilities. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Ontario. Registries. Reoperation. Retrospective Studies

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638059.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Mariani P, Ghanneme A, De la Rochefordière A, Girodet J, Falcou MC, Salmon RJ: Abdominoperineal resection for anal cancer. Dis Colon Rectum; 2008 Oct;51(10):1495-501
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominoperineal resection for anal cancer.
  • PURPOSE: Following initial radiotherapy or chemoradiotherapy for the treatment of anal cancer, patients who present with either persistent or locally recurrent disease are treated by abdominoperineal resection.
  • METHODS: Over a 34-year period (1969-2003), 422 patients with nonmetastatic anal cancer were treated with a curative intent.
  • RESULTS: Forty-one patients underwent abdominoperineal resection for persistent disease and 42 for locally recurrent disease.
  • Surgery, whether for persistent or locally recurrent disease, did not affect the 5-year survival rate.
  • CONCLUSIONS: Abdominoperineal resection for nonmetastatic anal cancer is associated with a high morbidity rate but may result in long-term survival regardless of the indication.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18521675.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. You YN, Larson DW, Dozois EJ, Nelson H, Antpack Filho E, Klein K, Miller RC: Multimodality salvage therapy for anal cancer failing standard chemoradiation. J Clin Oncol; 2009 May 20;27(15_suppl):e15635

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality salvage therapy for anal cancer failing standard chemoradiation.
  • : e15635 Background: Most squamous cell carcinomas of the anal canal (SCC) respond to chemoradiation, but effective therapy for locally-invasive(T4) or recurrent disease that fails standard chemoradiation and/or salvage abdominoperineal resection (APR) has not been clearly delineated.
  • METHODS: A prospective registry including 26 patients with locally-invasive or recurrent disease treated between 1993 and 2007 was reviewed.
  • Five-year OS were: 50%, 10%, and 22% for patients with locally-invasive, recurrent, and re-recurrent disease respectively.
  • CONCLUSIONS: For select patients with locally-persistent or recurrent SCC who fail standard primary treatment, a multimodality approach involving chemoradiation, extended pelvic resection and IORT offers a chance for improved survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962742.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Subramonia Iyer S, Akl A: A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004. J Clin Oncol; 2009 May 20;27(15_suppl):e15131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry: 1987-2004.
  • : e15131 Background: This paper describes the outcomes of patients with anal cancer enrolled in the Hurley Cancer Registry.
  • The Hurley cancer registry was searched using diagnosis codes for anal cancer.
  • The records retrieved, were reviewed for demographic and pathologic details,cancer recurrence, and vital status at last follow up.
  • RESULTS: Over a period of 18 years (1987 - 2004), there were 36 patients enrolled in the registry, with a diagnosis of anal cancer.
  • Five patients (14%) developed recurrent disease during follow up, after a median of 1.8 years (range: 0.67- 4.2 years).
  • Three of the five (60%) recurrent cancers were associated with HIV infection.
  • CONCLUSIONS: Among patients in the Hurley Cancer Registry, 1.
  • Squamous cell carcinoma is the commonest (75%) anal cancer.
  • 2. The risk of recurrence of anal cancer was 14% over 6-years, and 80% of recurrence was localised to the anal canal.
  • This was 78.9% for the subgroup of patients without recurrence, and 86.1% for the subgroup with recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960904.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Vorob'ev GI, Shelygin IuA, Nechushkin MI, Rybakov EG: [Results of surgical treatment of residual and recurrent anal tumors]. Khirurgiia (Mosk); 2008;(8):4-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of surgical treatment of residual and recurrent anal tumors].
  • Radio- or chemotherapy is a modern standard of anal cancer treatment.
  • The study is aimed to evaluate the role of abdominoperineal resection in the treatment of residual and recurrent anal cancer.
  • The complete tumor regression after radiotherapy/radiochemotherapy was achieved in 74(61.1%) of 120 patients with cancer-specific survival rate of 81.7%.
  • Thus, abdominoperineal resection remains the method of choice in the treatment of residual and recurrent anal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833142.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


18. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM: Magnetic resonance imaging of anal cancer. Clin Radiol; 2005 Oct;60(10):1111-9
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of anal cancer.
  • AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.
  • METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).
  • The size, extent and signal characteristics of the anal tumour were documented.
  • In all, 7 patients with recurrent disease underwent surgery and subsequent histological correlation was performed.
  • RESULTS: Primary and recurrent tumours were of high signal intensity relative to skeletal muscle on T2-weighted images (T2WI), and of low to intermediate signal intensity on T1-weighted images (T1WI).
  • Lymph node metastases were of similar signal intensity to the anal cancer.
  • Recurrent tumours were more locally advanced than primary tumours and extended into adjacent organs and the pelvic skeleton.
  • Recurrent lymph node disease involved perirectal, presacral and internal iliac nodes more commonly than did primary lymph node disease.
  • MR has a role in the preoperative evaluation and surgical planning of cases of recurrent disease following radiotherapy.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16179172.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Heyn J, Placzek M, Ozimek A, Baumgaertner AK, Siebeck M, Volkenandt M: Malignant melanoma of the anal region. Clin Exp Dermatol; 2007 Sep;32(5):603-7
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma of the anal region.
  • Malignant melanoma (MM) of the anal region is an uncommon disease.
  • Anorectal melanomas (AM) are most common in the rectum, followed by the anal canal and anal verge.
  • We report on a 39-year old man who presented with a 5-week history of recurrent prolapse of an anal tumour.
  • [MeSH-major] Anus Neoplasms. Melanoma
  • [MeSH-minor] Adult. Angiogenesis Inhibitors / therapeutic use. Cancer Vaccines / therapeutic use. Diagnosis, Differential. Humans. Interferon-alpha / therapeutic use. Male. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376215.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Cancer Vaccines; 0 / Interferon-alpha
  • [Number-of-references] 25
  •  go-up   go-down


21. Sheng XH, Gao CF, Ji XQ, Wei D, Zheng GB: [Comparative study of recurrent colon cancer and recurrent rectal cancer after radical resection]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Jun;13(6):409-12
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative study of recurrent colon cancer and recurrent rectal cancer after radical resection].
  • OBJECTIVE: To explore the difference in tumor biological behaviors and prognosis between recurrent colon cancer and recurrent rectal cancer after radical operation.
  • METHODS: Complete clinical and follow-up data of 132 patients with colorectal cancer developed recurrence,including 36 colon cancers and 96 rectal cancers, after curative resection were retrospectively analyzed and compared with respect of clinical pathological features and prognosis between colon and rectal cancer.
  • RESULTS: Significant differences were found in primary tumor gross type, histological type, tumor differentiation and lymph node metastasis between colon and rectal cancer(P<0.05).
  • Colon cancer recurred earlier than rectal cancer after radical surgery with the median time to recurrence being 14.0 months and 21.5 months, respectively(P=0.028).
  • The difference in multiple sites recurrence was also found between colon(n=16, 44.4%) and rectal cancer(n=65, 67.7%)(P=0.014).
  • The 3-year survival rate of recurrent rectal cancer was better than that of colon cancer (24.8% vs 15.6%, P=0.026).
  • CONCLUSION: There are some differences in tumor biological behaviors between colon and rectal cancer, and the prognosis of rectal cancer with recurrence is better than that of colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20577916.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


22. Iesalnieks I, Gaertner WB, Glass H, Strauch U, Hipp M, Agha A, Schlitt HJ: Fistula-associated anal adenocarcinoma in Crohn's disease. Inflamm Bowel Dis; 2010 Oct;16(10):1643-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma in Crohn's disease.
  • We present 6 patients with CD and fistula-associated anal adenocarcinoma (FAAA) and a systematic review of published series.
  • Mean delay of cancer diagnosis was 11 months.
  • Thirteen of 15 patients with node-positive tumors died with recurrent disease following surgery.
  • Periodical cancer surveillance should be performed in all patients with long-standing perianal CD fistulae.
  • [MeSH-major] Adenocarcinoma, Mucinous / etiology. Anus Neoplasms / etiology. Crohn Disease / complications. Rectal Fistula / etiology


23. Mai SK, Welzel G, Hermann B, Bohrer M, Wenz F: Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity. Onkologie; 2008 May;31(5):251-7
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome after combined radiochemotherapy for anal cancer - retrospective analysis of efficacy, prognostic factors, and toxicity.
  • BACKGROUND: This retrospective study evaluated the efficacy, prognostic factors, and toxicity of combined radiochemotherapy for anal cancer.
  • Higher T category was associated with inferior prognosis for colostomy-free survival (p = 0.000), male sex for local control (p = 0.004) and diseasespecific survival (p = 0.002), and tumor site at the anal margin for local control (p = 0.03).
  • 4 of 7 patients with recurrent anal margin tumors had human papillomavirus (HPV)-related disease.
  • CONCLUSION: Combined radiochemotherapy for anal cancer is a highly effective therapy with pronounced acute and minor late toxicity.
  • In the case of higher T stage, male sex, and cancer at the anal margin, treatment intensification should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Anus Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Radiotherapy / mortality. Risk Assessment / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18497514.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Vietharsdóttir H, Moeller PH, Jóhannsson J, Jónasson JG: [Anal cancer in Iceland 1987-2003. A population based study]. Laeknabladid; 2006 May;92(5):365-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal cancer in Iceland 1987-2003. A population based study].
  • [Transliterated title] Carcinoma ani á Islandi 1987-2003 -- lýethgrundueth rannsókn.
  • OBJECTIVE: Anal cancer is a rare disease.
  • The aim of this study was to describe anal cancer in Iceland in 1987-2003 with respect to incidence, histologic type, treatment, recurrence rate and survival.
  • MATERIAL AND METHODS: This is a retrospective study in which all malignant anal tumours diagnosed in Iceland in the period 1987-2003 were reviewed with respect to patient outcome.
  • This is a nationwide, population-based study of malignant tumours of the anal region.
  • RESULTS: From 1987-2003 thirty-eight patients were diagnosed with anal cancer, 28 females and 10 males.
  • Age standardized incidence rates for anal cancer in Iceland were 0.3 (+/-0.2) of 100.000 males and 0.9 (+/-0.4) of 100.000 females.
  • Most patients had squamous cell carcinoma (n=30).
  • The remaining histologic types were malignant melanoma (n=3), adenosquamous carcinoma (n=1), adenocarcinoma (n=1), GIST (n=1) and undifferentiated carcinoma (n=2).
  • Twelve patients had recurrent cancer.
  • The mean value of the time from diagnosis of the primary to the recurrent cancer was 15.6 months (range, 5.9-117).
  • Sixteen patients remain with disease and ten have died of anal cancer.
  • The five year survival rate for patients diagnosed in the years 1987 to 1998 is 75% but cancer-specific survival is 82%.
  • CONCLUSION: Age-standardized incidence for anal cancer in Iceland is similar to other regions.
  • The proportion of adenocarcinoma of the anus is lower in Iceland than elsewhere.
  • [MeSH-major] Anus Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Carcinoma / epidemiology. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Squamous Cell / epidemiology. Defecation. Female. Gastrointestinal Hemorrhage / etiology. Humans. Iceland / epidemiology. Incidence. Male. Melanoma / epidemiology. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Pain / etiology. Pruritus / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16741319.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


25. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D: Early detection of recurrent breast cancer using metabolite profiling. Cancer Res; 2010 Nov 1;70(21):8309-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of recurrent breast cancer using metabolite profiling.
  • We report on the development of a monitoring test for recurrent breast cancer, using metabolite-profiling methods.
  • Using a combination of nuclear magnetic resonance (NMR) and two-dimensional gas chromatography-mass spectrometry (GC×GC-MS) methods, we analyzed the metabolite profiles of 257 retrospective serial serum samples from 56 previously diagnosed and surgically treated breast cancer patients.
  • One hundred sixteen of the serial samples were from 20 patients with recurrent breast cancer, and 141 samples were from 36 patients with no clinical evidence of the disease during ∼6 years of sample collection.
  • Strikingly, 55% of the patients could be correctly predicted to have recurrence 13 months (on average) before the recurrence was clinically diagnosed, representing a large improvement over the current breast cancer-monitoring assay CA 27.29.
  • To the best of our knowledge, this is the first study to develop and prevalidate a prediction model for early detection of recurrent breast cancer based on metabolic profiles.
  • In particular, the combination of two advanced analytical methods, NMR and MS, provides a powerful approach for the early detection of recurrent breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] NMR Biomed. 2002 Aug;15(5):327-37 [12203224.001]
  • [Cites] Br J Cancer. 2002 Apr 22;86(8):1217-22 [11953875.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1875-82 [6090002.001]
  • [Cites] Cancer. 1992 May 1;69(9):2343-8 [1562982.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):420-7 [7812974.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2322-8 [9196146.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3791-9 [9731486.001]
  • [Cites] J Magn Reson. 1998 Nov;135(1):194-202 [9799694.001]
  • [Cites] J Magn Reson Imaging. 1998 Nov-Dec;8(6):1191-7 [9848727.001]
  • [Cites] Clin Chem. 1999 May;45(5):630-7 [10222349.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3A):1737-46 [10470108.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):782-8 [15499633.001]
  • [Cites] Semin Cancer Biol. 2005 Aug;15(4):267-76 [15894488.001]
  • [Cites] NMR Biomed. 2006 Feb;19(1):30-40 [16229059.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):345-51 [16410341.001]
  • [Cites] Nature. 2006 Apr 20;440(7087):1073-7 [16625200.001]
  • [Cites] BMC Cancer. 2006;6:220 [16953875.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6 [17202168.001]
  • [Cites] Anal Bioanal Chem. 2007 Jan;387(2):525-7 [16955259.001]
  • [Cites] Breast Cancer Res Treat. 2007 Aug;104(2):181-9 [17061040.001]
  • [Cites] Pac Symp Biocomput. 2007;:157-68 [17990489.001]
  • [Cites] Pac Symp Biocomput. 2007;:181-92 [17990491.001]
  • [Cites] J Clin Oncol. 2007 Nov 20;25(33):5287-312 [17954709.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83 [18695137.001]
  • [Cites] Cell. 2008 Sep 5;134(5):714-7 [18775301.001]
  • [Cites] Expert Rev Mol Diagn. 2008 Sep;8(5):617-33 [18785810.001]
  • [Cites] Nature. 2009 Feb 12;457(7231):910-4 [19212411.001]
  • [Cites] Breast Cancer Res Treat. 2009 Apr;114(3):403-12 [18421576.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1505-10 [19297316.001]
  • [Cites] J Proteome Res. 2010 Feb 5;9(2):972-9 [19994911.001]
  • [Cites] Cancer Biol Ther. 2010 Feb;9(4):266-73 [20026902.001]
  • [Cites] Xenobiotica. 1999 Nov;29(11):1181-9 [10598751.001]
  • [Cites] Oncology. 2000 Apr;58(3):185-90 [10765118.001]
  • [Cites] Cancer Treat Rev. 2000 Apr;26(2):91-102 [10772967.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):688-95 [11830521.001]
  • [Cites] Anticancer Res. 2001 Nov-Dec;21(6A):4105-8 [11911301.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3195-201 [12810648.001]
  • (PMID = 20959483.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM085291; United States / NCI NIH HHS / CA / R25 CA128770; United States / NIGMS NIH HHS / GM / R01GM085291-02; United States / NCI NIH HHS / CA / R25CA128770
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  • [Other-IDs] NLM/ NIHMS232187; NLM/ PMC2995269
  •  go-up   go-down


26. Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD: Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis Colon Rectum; 2008 Jul;51(7):1061-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fistula-associated anal adenocarcinoma: good results with aggressive therapy.
  • PURPOSE: To evaluate the clinical features, pathology, treatment, and outcome of patients with fistula-associated anal adenocarcinoma.
  • METHODS: We identified 14 patients with histologically proven fistula-associated anal adenocarcinoma.
  • RESULTS: Nine patients presented with a persistent fistula, 3 with a perianal mass, 1 with pain and drainage, and 1 with a recurrent perianal abscess.
  • Eleven patients had preexisting chronic anal fistulas.
  • The diagnosis of cancer was suspected during physical examination in 6 of the 14 patients (43 percent).
  • CONCLUSIONS: The diagnosis of fistula-associated anal adenocarcinoma is often unsuspected.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18418652.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Uchikoshi F, Nishida T, Ueshima S, Nakahara M, Matsuda H: Laparoscope-assisted anal sphincter-preserving operation preceded by transanal procedure. Tech Coloproctol; 2006 Mar;10(1):5-9; discussion 9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscope-assisted anal sphincter-preserving operation preceded by transanal procedure.
  • BACKGROUND: Transanal intersphincteric resection (ISR) was introduced and has been increasingly performed as an ultimate surgical treatment for extremely low rectal cancer.
  • METHODS: Between December 2003 and June 2004, we performed laparoscope-assisted ISR for two patients with very low rectal cancer and total colectomy for two patients with ulcerative colitis complicated by colorectal cancer.
  • All patients showed favorable recovery including postoperative anal function with no complication or recurrent disease.
  • CONCLUSIONS: This procedure is feasible and has favorable short-term results for radical treatment of very low rectal disease, while preserving anal function.
  • [MeSH-major] Anal Canal / surgery. Proctoscopy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528490.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


28. Kidd EA, Dehdashti F, Siegel BA, Grigsby PW: Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol; 2010 Jun;95(3):288-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis.
  • PURPOSE: To evaluate anal cancer uptake of F-18 fluorodeoxyglucose (FDG) measured as the maximum standardized uptake value (SUV(max)) by positron emission tomography (PET) and its correlation with prognostic factors.
  • PATIENTS AND METHODS: The study population consisted of 77 patients with stages 0-IIIB anal cancer who underwent pre-treatment FDG-PET.
  • Patients with high anal tumor SUV(max) at diagnosis were at an increased risk of persistent or recurrent disease on post-therapy FDG-PET performed less than 4months after completing therapy (p=0.0402).
  • CONCLUSIONS: SUV(max) is a valuable biomarker of anal cancer prognosis, predicting increased risk of lymph node metastasis and worse disease-free survival.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Positron-Emission Tomography. Radiopharmaceuticals / pharmacokinetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20231040.001).
  • [ISSN] 1879-0887
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


29. Hogg ME, Popowich DA, Wang EC, Kiel KD, Stryker SJ, Halverson AL: HIV and anal cancer outcomes: a single institution's experience. Dis Colon Rectum; 2009 May;52(5):891-7
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV and anal cancer outcomes: a single institution's experience.
  • PURPOSE: The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.
  • METHODS: A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.
  • RESULTS: Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer.
  • Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009).
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality. HIV Infections / mortality


30. Puglisi M, Varaldo E, Assalino M, Ansaldo G, Torre G, Borgonovo G: Anal metastasis from recurrent breast lobular carcinoma: a case report. World J Gastroenterol; 2009 Mar 21;15(11):1388-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal metastasis from recurrent breast lobular carcinoma: a case report.
  • We report a case of isolated gastrointestinal metastasis from breast lobular carcinoma, which mimicked primary anal cancer.
  • In July 2000, an 88-year-old woman presented with infiltrating lobular cancer (pT1/G2/N2).
  • Four years later, she presented with an anal polypoid lesion.
  • [MeSH-major] Anus Neoplasms / secondary. Breast Neoplasms / pathology. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):136-41 [1568609.001]
  • [Cites] J Surg Oncol. 1992 Nov;51(3):211-5 [1434649.001]
  • [Cites] Surgery. 1993 Oct;114(4):637-41; discussion 641-2 [8211676.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):368-72 [2050370.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1745-50 [16721370.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):453-5 [11289296.001]
  • [Cites] Ann Oncol. 2003 Jan;14(1):71-3 [12488295.001]
  • [Cites] Ann Chir. 1983 May;37(4):281-4 [6625502.001]
  • [Cites] Ann Surg. 1986 Mar;203(3):307-10 [3954484.001]
  • [Cites] Int J Biol Markers. 1988 Jan-Mar;3(1):41-8 [2854832.001]
  • [Cites] Tech Coloproctol. 2005 Dec;9(3):237-8 [16328121.001]
  • (PMID = 19294770.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2658842
  •  go-up   go-down


31. Haboubi NY, Edilbe MW, Hill J: Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline. Colorectal Dis; 2007 Mar;9(3):238-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Justification for staging of epidermoid anal carcinoma after salvage surgery: a pathological guideline.
  • The currently accepted first line treatment for epidermoid anal cancer is chemoradiotherapy (CRT).
  • Residual or recurrent disease following initial CRT, is best treated by salvage anorectal excision.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17298622.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, Minsky BD, Cohen AM, Paty PB: Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum; 2005 Jun;48(6):1169-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical salvage of recurrent rectal cancer after transanal excision.
  • PURPOSE: This study examines surgical salvage of locally recurrent rectal cancer following transanal excision of early tumors.
  • METHODS: Through retrospective review of a colorectal database we identified 50 patients who underwent attempted surgical salvage for local recurrence following initial transanal excision of T1 or T2 rectal cancer.
  • CONCLUSION: Pelvic recurrence following transanal excision of early rectal cancer is often locally advanced, requiring an extended pelvic dissection with en bloc resection of adjacent pelvic organs to achieve salvage.
  • When contemplating local excision for early rectal cancer, the risk of local recurrence, the extent and morbidity of surgery required for salvage, and the modest cure rate following salvage should be considered.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Colectomy. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Pelvic Exenteration. Reoperation. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793645.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Chen YW, Yen SH, Chen SY, Huang PI, Shiau CY, Liu YM, Lin JK, Wang LW: Anus-preservation treatment for anal cancer: retrospective analysis at a single institution. J Surg Oncol; 2007 Oct 1;96(5):374-80
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
  • BACKGROUND: To evaluate anus-preservation treatment for anal cancer.
  • METHODS: Review of 42 patients (24 M/18 F; median age, 70 years; range, 13-95) with stage I-IIIB disease (squamous cell carcinoma [SqCC], 33; adenocarcinoma, 9) who received curative radiotherapy between 1991 and 2004.
  • The complete response rate was 67% (SqCC, 23/33; adenocarcinoma, 5/9); of 12 patients who failed treatment, primary tumor was the recurrent site in seven (median failure time, 5 months): six patients underwent salvage abdominoperineal resection.
  • Five-year functional anus-preservation rate was 64%.
  • CONCLUSION: With careful monitoring of toxicity, non-surgical anus-preservation treatment with good tumor control is feasible.
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 17492635.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Tilney HS, Heriot AG, Trickett JP, Massouh H, Edwards DP, Mellor SG, Gudgeon AM: The use of intra-operative endo-anal ultrasound in perianal disease. Colorectal Dis; 2006 May;8(4):338-41
MedlinePlus Health Information. consumer health - Anal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of intra-operative endo-anal ultrasound in perianal disease.
  • Pathologies encountered were fistula-in-ano (42%), fissure-in-ano (26%), complicated perianal sepsis (16%) and carcinoma (5%).
  • In 22 cases (51.2%) the EAUS findings affected the surgical management (extent of muscle above a fistula 9 cases, extent of sphincterotomy 7 cases, site of sepsis identified 2 cases, exclusion of sepsis 2 cases, assessment of cancer resectability 1 case, biopsy of intersphincteric lesion 1 case).
  • While not essential, it is a useful adjunct especially in recurrent perianal sepsis, undiagnosed anorectal pain and anal fissure.
  • [MeSH-major] Anus Diseases / surgery. Anus Diseases / ultrasonography. Endosonography. Intraoperative Care. Rectal Fistula / surgery. Rectal Fistula / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630240.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Nørgaard M, Laurberg S: Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol; 2009 Jan;16(1):68-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap.
  • Salvage surgery of recurrent or persistent anal cancer following radiotherapy is often followed by perineal wound complications.
  • We examined survival and perineal wound complications in anal cancer salvage surgery during a 10-year period with primary perineal reconstruction predominantly performed using vertical rectus abdominis myocutaneous (VRAM) flap.
  • Between 1997 and 2006, 49 patients underwent anal cancer salvage surgery.
  • We conclude that anal cancer salvage surgery can yield long-time survival but obtaining free margins is critical.
  • [MeSH-major] Anus Neoplasms / mortality. Anus Neoplasms / surgery. Perineum / surgery. Reconstructive Surgical Procedures. Rectus Abdominis / transplantation. Surgical Flaps. Wound Healing
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Postoperative Complications / diagnosis. Postoperative Complications / therapy. Salvage Therapy. Survival Rate. Time Factors. Treatment Outcome


36. Chen BE, Cook RJ: The analysis of multivariate recurrent events with partially missing event types. Lifetime Data Anal; 2009 Mar;15(1):41-58
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The analysis of multivariate recurrent events with partially missing event types.
  • In many clinical studies, subjects are at risk of experiencing more than one type of potentially recurrent event.
  • Here we describe a likelihood approach based on joint models for the multi-type recurrent events where parameter estimation is obtained from a Monte-Carlo EM algorithm.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18622700.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW: Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol; 2007 Feb;14(2):478-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal.
  • BACKGROUND: The standard treatment for epidermoid carcinoma of the anal canal consists of combined radiation and chemotherapy.
  • For patients who present with persistent or locally recurrent disease, salvage abdominoperineal resection is the treatment of choice.
  • RESULTS: Eleven patients underwent radical salvage surgery for persistent disease and 20 patients for recurrent disease.
  • Twelve patients developed recurrent disease after radical salvage surgery.
  • Factors that were not found to have an impact on survival included the presence of persistent versus recurrent disease, tumor (T) stage, and margin status of resection.
  • CONCLUSIONS: Long-term survival following salvage surgery for persistent or locally recurrent epidermoid carcinoma of the anal canal can be achieved in the majority of patients.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17103253.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Lisi G, Illiceto MT, Rossi C, Broto JM, Jil-Vernet JM, Lelli Chiesa P: Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments. Pediatr Surg Int; 2006 Dec;22(12):967-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal canal duplication: a retrospective analysis of 12 cases from two European pediatric surgical departments.
  • Anal canal duplication (ACD) represents an extremely rare intestinal congenital anomaly of unknown origin.
  • The confirmative diagnosis is histopathological, with evidence of an anal mucosal lining (squamous +/- transitional epithelium), surrounded from a smooth muscle coat and anal glands.
  • According to clinical presentation, patients could be divided in three age groups: asymptomatic (mean age 4.8 months, six patients - one with an associated complex genitourinary malformation, one with a presacral mature teratoma, one with ACD evidenced hysthologically on a retroanal mass removed during the correction of an ARM), mildly symptomatic - constipation, mucous discharge (mean age 29.2 months, four patients - one with associated presacral ependymoma and intestinal neuronal dysplasia type B, one with presacral mass) and complicated - perineal abscess, recurrent fistula (mean age 34 months, two patients).
  • Surgical early removal (mucosectomy or perineal/posterior sagittal approach, depending on length of ACD and associated presacral mass) is warranted, also in asymptomatic patients, because of the risk of inflammatory complications and cancer (the latter reported in literature in adults).
  • [MeSH-major] Anal Canal / abnormalities. Anal Canal / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17061104.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


39. Kumar GK, Chandra SS, Krishnan R: Local excision inadequate in the treatment of anal canal leiomyosarcoma. Saudi J Gastroenterol; 2010 Jul-Sep;16(3):226-7
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local excision inadequate in the treatment of anal canal leiomyosarcoma.
  • Leiomyosarcoma of the anal canal is an uncommon neoplasm of the gastrointestinal tract.
  • We report a 45-year-old lady with anal canal leiomyosarcoma.
  • In the setting of a recurrent tumor with high-grade histological appearance, local excision would be deemed unsafe.
  • [MeSH-major] Anal Canal / surgery. Anus Neoplasms / surgery. Leiomyosarcoma / surgery

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 1993 Sep;63(9):703-9 [8363480.001]
  • [Cites] J Chir (Paris). 1988 Apr;125(4):245-8 [3392131.001]
  • [Cites] Postgrad Med J. 1996 May;72(847):304-6 [8761508.001]
  • [Cites] J Med Assoc Ga. 1991 Dec;80(12):685-99 [1800593.001]
  • [Cites] Cancer. 1991 Oct 1;68(7):1640-3 [1893364.001]
  • (PMID = 20616423.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3003215
  •  go-up   go-down


40. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • Resection is now reserved for persistent or recurrent disease.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Tokar M, Bobilev D, Zalmanov S, Geffen DB, Walfisch S: Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature. Onkologie; 2006 Feb;29(1-2):30-2
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined multimodal approach to the treatment of metastatic anal carcinoma: report of a case and review of the literature.
  • BACKGROUND: We report on a patient with squamous cell anal carcinoma and liver metastases, who underwent multimodal treatment for cure, consisting of repeated partial hepatectomy in combination with chemoradiotherapy.
  • PATIENTS AND METHODS: A 54-year-old woman presented with squamous cell anal carcinoma and liver metastases.
  • 2 and 5 years after presentation, the patient underwent repeated partial hepatectomies for recurrent liver disease.
  • RESULTS: Repeated partial hepatectomy led to prolonged survival in a patient with squamous cell anal carcinoma metastatic to the liver.
  • CONCLUSIONS: This is the first report of aggressive partial hepatectomy for recurrent liver metastases resulting from anal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2006 Feb;29(1-2):5-6 [16514247.001]
  • (PMID = 16514253.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 19
  •  go-up   go-down


42. Zampino MG, Magni E, Sonzogni A, Renne G: K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment? Cancer Chemother Pharmacol; 2009 Dec;65(1):197-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?
  • PURPOSE: Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1-5% of all intestinal tumours.
  • The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated.
  • This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease.
  • [MeSH-major] Anus Neoplasms / genetics. Carcinoma, Squamous Cell / genetics. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19727729.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


43. Lee J, Corman M: Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature. J Gastrointest Surg; 2009 Jan;13(1):150-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of anal adenocarcinoma after local excision and adjuvant chemoradiation therapy: report of a case and review of the literature.
  • INTRODUCTION: Tumors arising from the anal canal are rare, comprising 1.5% of all gastrointestinal tumors in the USA.
  • The vast majority of these anal cancers are epidermoid (cloacogenic/basaloid and squamous cell carcinomas), while adenocarcinomas reportedly occur 5% to 19% of the time.
  • Because of its rarity, reports about anal adenocarcinoma are limited to small retrospective studies and case reports.
  • Moreover, no series has directly compared outcomes between patients undergoing the various available treatment options, making it difficult to determine the optimal treatment for this aggressive cancer.
  • Current management of this cancer remains controversial, with some authors believing abdominoperineal resection with permanent colostomy should be considered the standard treatment.
  • CASE PRESENTATION: We describe a case of recurrent anal adenocarcinoma after conservative management with local excision and adjuvant chemoradiation therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Antineoplastic Agents / therapeutic use. Anus Neoplasms / pathology. Anus Neoplasms / therapy. Colectomy / methods

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810561.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


44. Nahas SC, Nahas CS, Silva Filho EV, Levi JE, Atui FC, Marques CF: Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report. Sao Paulo Med J; 2007 Sep 6;125(5):292-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perianal squamous cell carcinoma with high-grade anal intraepithelial neoplasia in an HIV-positive patient using highly active antiretroviral therapy: case report.
  • CONTEXT: Highly active antiretroviral therapy (HAART) has turned human immunodeficiency virus (HIV) infection into a chronic condition, and this has led to increased incidence of anal dysplasia among HIV-positive patients.
  • Routine anal evaluation including the anal canal and perianal area is recommended for this population, especially for patients infected by oncogenic human papillomavirus (HPV) types.
  • CASE REPORT: A 54-year-old homosexual HIV-positive man presented with a six-year history of recurrent perianal and anal warts.
  • He presented some condylomatous spreading lesions occupying part of the anal canal and the perianal skin, and also a well-demarcated slightly painful perianal plaque of dimensions 1.0 x 1.0 cm.
  • Both anal canal Pap smears and biopsies guided by high-resolution anoscopy revealed high-grade squamous intraepithelial lesion.
  • HPV DNA testing of the anus detected the presence of HPV-16 type.
  • Histological analysis on the excised tissue revealed high-grade squamous intraepithelial lesion with one focus of microinvasive squamous cell cancer measuring 1 mm.
  • The patient showed pathological evidence of recurrent anal and perianal high-grade squamous intraepithelial lesions at the sixth-month follow-up and required further ablation of those lesions.
  • However no invasive squamous cell carcinoma recurrence has been detected so far.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / adverse effects. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. HIV Seropositivity / drug therapy. Human papillomavirus 16 / isolation & purification. Papillomavirus Infections / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. DNA, Viral / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnosis


45. Kuramoto L, Sobolev BG, Donaldson MG: On reporting results from randomized controlled trials with recurrent events. BMC Med Res Methodol; 2008;8:35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On reporting results from randomized controlled trials with recurrent events.
  • Although a variety of statistical methods are available for the analysis of recurrent events, reporting the effect of an intervention on outcomes that recur is an area that remains poorly understood in clinical research.
  • The purpose of this paper is to outline guidelines for reporting results from RCTs where the outcome of interest is a recurrent event.
  • We reviewed the utility of regression models for the rate of a recurrent event by articulating the associated study questions, preenting the risk sets, and interpreting the regression coefficients.
  • RESULTS: Based on a single data set produced by simulation, we reported and contrasted results from statistical methods for evaluating treatment effect from an RCT with a recurrent outcome.
  • CONCLUSION: Our guidelines for reporting results from an RCT involving a recurrent event suggest that the study question and the objectives of the trial, such as assessing comparable groups and estimating effect size, should determine the statistical methods.
  • The guidelines should allow clinical researchers to report appropriate measures from an RCT for understanding the effect of intervention on the occurrence of a recurrent event.

  • MedlinePlus Health Information. consumer health - Falls.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1194-204 [17540006.001]
  • [Cites] BMJ. 1997 Oct 25;315(7115):1065-9 [9366737.001]
  • [Cites] Lancet. 2001 Apr 14;357(9263):1191-4 [11323066.001]
  • [Cites] Stat Methods Med Res. 2002 Apr;11(2):141-66 [12040694.001]
  • [Cites] Eur Heart J. 2003 Jan;24(1):105-12 [12559942.001]
  • [Cites] N Engl J Med. 1988 Dec 29;319(26):1701-7 [3205267.001]
  • [Cites] Lancet. 1999 Jan 9;353(9147):93-7 [10023893.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):530-4 [15933397.001]
  • [Cites] Stat Med. 2006 Jan 15;25(1):165-79 [16217859.001]
  • [Cites] Lifetime Data Anal. 2006 Mar;12(1):69-95 [16583300.001]
  • [Cites] Spine J. 2006 Sep-Oct;6(5):488-93 [16934716.001]
  • [Cites] Stat Med. 2006 Oct 30;25(20):3518-33 [16345026.001]
  • [Cites] Lifetime Data Anal. 2006 Dec;12(4):389-406 [17031499.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2007 Apr;62(4):415-9 [17452736.001]
  • [Cites] Stat Methods Med Res. 2007 Apr;16(2):103-22 [17484295.001]
  • [Cites] Pulm Pharmacol Ther. 2008;21(1):88-97 [17350868.001]
  • [Cites] JAMA. 1989 May 12;261(18):2663-8 [2709546.001]
  • [Cites] J Gerontol. 1989 Jul;44(4):M112-7 [2738307.001]
  • [Cites] Am J Epidemiol. 1993 Feb 1;137(3):342-54 [8452142.001]
  • [Cites] BMJ. 1995 Feb 18;310(6977):454-6 [7873955.001]
  • [Cites] Stat Med. 1995 Oct 15;14(19):2081-98 [8552888.001]
  • [Cites] Stat Med. 1997 Sep 30;16(18):2029-47 [9308130.001]
  • [Cites] Stat Med. 2000 Jan 15;19(1):13-33 [10623910.001]
  • (PMID = 18513418.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2438437
  •  go-up   go-down


46. Stewart D, Yan Y, Kodner IJ, Birnbaum E, Fleshman J, Myerson R, Dietz D: Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors? J Gastrointest Surg; 2007 Dec;11(12):1744-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery after failed chemoradiation for anal canal cancer: should the paradigm be changed for high-risk tumors?
  • It is common belief that patients failing chemoradiation therapy (CRT) for squamous cell cancer of the anus (SCCA) can be salvaged with subsequent surgery.
  • The aim of this study was to examine our experience with abdominoperineal resection (APR) in cases of persistent or recurrent SCCA with an emphasis on survival and morbidity.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Salvage Therapy


47. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


48. Uemura M, Ikeda M, Sekimoto M, Haraguchi N, Mizushima T, Yamamoto H, Takemasa I, Ishii H, Mori M: Prevention of severe pelvic abscess formation following extended radical surgery for locally recurrent rectal cancer. Ann Surg Oncol; 2009 Aug;16(8):2204-10
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of severe pelvic abscess formation following extended radical surgery for locally recurrent rectal cancer.
  • BACKGROUND: For treatment of locally recurrent rectal cancer (LRRC), extended radical surgery is sometimes required to obtain a negative margin.
  • The aim of this study was to determine the effects of reconstructive surgery using a large rectus abdominis myocutaneous (RAM) flap and anal preservation surgery on the incidence of severe PA.
  • To reduce the risk of infections, we modified the surgical approach after 2004 to include a larger volume of RAM flap (modified RAM flap) and implemented anal preservation surgery.
  • The incidence of severe PA was lower in the anal preservation group [1 of 12 (8.3%)] compared with those who did not undergo such surgery [14 of 32 (44%), P = 0.035].
  • All three patients who underwent anal preservation and modified RAM flap reconstruction did not develop severe PA.
  • Multiple logistic analysis identified no anal preservation (Odds ratio [OR] = 10.6) and performing of sacrectomy (OR = 20.0) as risk factors for severe PA.
  • CONCLUSION: Anal preservation surgery is an effective measure against the development of severe PA after radical resection of LRRC.
  • [MeSH-minor] Adult. Aged. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Wound Healing

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19506961.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Handisurya A, Rieger A, Bago-Horvath Z, Schellenbacher C, Bankier A, Salat A, Stingl G, Kirnbauer R: Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect; 2009 Aug;85(4):261-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient.
  • BACKGROUND: Buschke-Löwenstein tumour (BLT) of the anogenitalia is a locally invasive, destructively growing verrucous carcinoma that does not metastasise.
  • Nevertheless, the tumour grows relentlessly and may rarely progress into squamous cell cancer (SCC).
  • RESULTS: A human immunodeficiency virus (HIV)-infected immunosuppressed patient developed (peri)anal warts accompanied by recurrent abscesses and fistulae.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. HIV Infections / complications. Immunocompromised Host
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / virology. Anti-HIV Agents / therapeutic use. Cachexia / etiology. Fatal Outcome. Groin. HIV Seropositivity / drug therapy. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness


50. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • Despite treatment, three patients progressed to invasive cancer (1.2 percent).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Ota Y, Takagi Y, Osaka Y, Hoshino S, Shinohara M, Sudo H, Tsuchida A, Aoki T: [A case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stent-in-stent placement was effective]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2042-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stent-in-stent placement was effective].
  • OBJECTIVES: We report one case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stenting was effective and good QOL was achieved.
  • In July 2000, the patient underwent total gastrectomy.Roux-en Y reconstruction with a diagnosis of gastric cancer.
  • Based on a biopsy of the stenosis, a diagnosis of post-operative recurrent gastric cancer was made.
  • METHOD: After a guide wire was endoscopically inserted and a good passage on the anal side of the stenosis was confirmed, a stent was placed.
  • CONCLUSION: Stenting is relatively simple and less invasive, which is useful for the improvement of QOL and in recurrent cases as well.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106517.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Bratasz A, Weir NM, Parinandi NL, Zweier JL, Sridhar R, Ignarro LJ, Kuppusamy P: Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin. Proc Natl Acad Sci U S A; 2006 Mar 7;103(10):3914-9
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.
  • Ovarian cancer is a gynecological malignancy that is commonly treated by cytoreductive surgery followed by cisplatin treatment.
  • However, the cisplatin treatment, although successful initially, is not effective in the treatment of the recurrent disease that invariably surfaces within a few months of the initial treatment.
  • We used NCX-4016 [2-(acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester], a derivative of aspirin containing a nitro group that releases nitric oxide in a sustained fashion for several hours in cells and in vivo, and we studied its cytotoxic efficacy against human ovarian cancer cells (HOCCs).
  • In conclusion, this study showed that NCX-4016 is a potential inhibitor of the proliferation of CR HOCCs and thus might specifically kill cisplatin-refractory cancer cells in patients with recurrent ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8306-11 [12048254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1689-94 [11818533.001]
  • [Cites] Nat Rev Drug Discov. 2002 May;1(5):375-82 [12120413.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):529-36 [12217790.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Dec;303(3):1273-82 [12438552.001]
  • [Cites] Circulation. 2002 Dec 10;106(24):3120-5 [12473561.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8497-502 [15173604.001]
  • [Cites] Anal Biochem. 1989 Oct;182(1):58-63 [2557778.001]
  • [Cites] Biochem Pharmacol. 1992 Sep 25;44(6):1149-57 [1358072.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):644-9 [8420689.001]
  • [Cites] Magn Reson Med. 1996 Aug;36(2):212-8 [8843374.001]
  • [Cites] Life Sci. 1998;62(23):PL 367-73 [9627095.001]
  • [Cites] Nitric Oxide. 1997 Feb;1(1):88-94 [9701048.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):516-25 [15695394.001]
  • [Cites] J Pharm Biomed Anal. 2002 Aug 1;29(6):1061-71 [12110391.001]
  • [Cites] Br J Pharmacol. 2000 Jan;129(2):343-50 [10694241.001]
  • [Cites] Nitric Oxide. 2000 Oct;4(5):496-504 [11020338.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5245-54 [11046058.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2860-4 [11226331.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4202-8 [11259671.001]
  • [Cites] Br J Pharmacol. 2001 Aug;133(8):1314-22 [11498517.001]
  • [Cites] J Pharm Biomed Anal. 2001 Nov;26(4):509-18 [11516901.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • [Cites] Ann Oncol. 2001 Sep;12(9):1195-203 [11697824.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4337-8 [16537366.001]
  • (PMID = 16497833.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR003048; United States / NCRR NIH HHS / RR / G12 RR003048; United States / NCI NIH HHS / CA / R01 CA102264; United States / NCI NIH HHS / CA / CA78886; United States / NCI NIH HHS / CA / R01 CA078886; United States / NCI NIH HHS / CA / CA102264
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Nitric Oxide Donors; 175033-36-0 / nitroaspirin; 31C4KY9ESH / Nitric Oxide; GAN16C9B8O / Glutathione; Q20Q21Q62J / Cisplatin; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC1450164
  •  go-up   go-down


53. Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IeM: Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas. J Oncol; 2010;2010:285191
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.
  • Our previous reports demonstrated that NAC1, a BTB/POZ domain-containing nuclear protein, upregulates in recurrent ovarian serous carcinoma and participates in developing drug resistance in cancer cells.
  • Immunohistochemistry showed that NAC1 and FASN immunointensities in ovarian serous carcinoma tissues had a highly significant correlation (P < .0001).
  • Moreover, we found that recurrent serous carcinomas exhibited higher FASN immunointensities than their matched primary tumors (P < .001).
  • Finally, C93, a new FASN inhibitor, induced massive apoptosis in carboplatin/paclitaxel resistant ovarian cancer cells.
  • The dependence of drug resistant tumor cells on FASN suggests a potential application of FASN-based therapeutics for recurrent ovarian cancer patients.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9267-71 [1409633.001]
  • [Cites] Cell. 2008 Mar 21;132(6):1049-61 [18358816.001]
  • [Cites] Urology. 1995 Jan;45(1):81-6 [7817483.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):474-82 [8630954.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1189-93 [8640795.001]
  • [Cites] Hum Pathol. 1996 Sep;27(9):917-21 [8816886.001]
  • [Cites] Clin Cancer Res. 2008 Apr 15;14(8):2458-64 [18413838.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3149-55 [18483383.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2616-8 [18509172.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4088-97 [18682509.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5332-40 [18765524.001]
  • [Cites] Biochem J. 2009 Jan 1;417(1):313-22 [18774944.001]
  • [Cites] Gynecol Oncol. 2008 Dec;111(3):478-86 [18823650.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1340-8 [18838960.001]
  • [Cites] Mol Cancer Ther. 2008 Dec;7(12):3816-24 [19074856.001]
  • [Cites] Neurochem Int. 2009 Mar-Apr;54(3-4):245-52 [19121354.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):214-24 [19139131.001]
  • [Cites] Oncogene. 2009 May 7;28(18):1941-8 [19305429.001]
  • [Cites] J Biol Chem. 2009 Jun 12;284(24):16071-81 [19366700.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jul 31;385(3):454-9 [19467222.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):201-8 [9006336.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):686-92 [9191002.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4285-300 [9331090.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4611-5 [9788612.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2115-20 [9815604.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):2114-23 [11448931.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Mol Cancer Res. 2003 Aug;1(10):707-15 [12939396.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3574-82 [15806173.001]
  • [Cites] J Neurochem. 2005 Aug;94(3):786-93 [16033423.001]
  • [Cites] Trends Pharmacol Sci. 2005 Nov;26(11):541-4 [16169094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5977-80 [16778164.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] J Neurochem. 2007 May;101(3):611-8 [17254023.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):1030-6 [17391728.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2964-71 [17409402.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Cancer Biol Ther. 2007 Aug;6(8):1263-8 [17786030.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):973-80 [17786362.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):8058-64 [17804717.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6842-9 [17982121.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11933-41 [18089824.001]
  • [Cites] Bioinformatics. 2008 Feb 15;24(4):458-61 [18203771.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):1003-11 [18281474.001]
  • [Cites] Mol Cancer Ther. 2008 Feb;7(2):263-70 [18281512.001]
  • [Cites] J Pathol. 1995 Aug;176(4):343-52 [7562249.001]
  • (PMID = 20508725.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2873657
  •  go-up   go-down


54. Egawa T, Nagashima A, Kitano M, Doi M, Hayashi S, Sekine K, Ito Y, Shimizu M, Yoshii H: [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2053-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
  • An 80-year-old female visited our hospital with a chief complaint of anal pain and bleeding.
  • The patient was diagnosed by colonoscopy to have rectal cancer which invaded the perineal region.
  • As a result, this regimen was thus found to be promising for unresectable or recurrent colorectal cancer in elder patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219896.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


55. Sandiford N, Prussia PR, Chiappa A, Zbar AP: Synchronous mucinous adenocarcinoma of the rectosigmoid seeding onto a pre-existing anal fistula. Int Semin Surg Oncol; 2006;3:25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous mucinous adenocarcinoma of the rectosigmoid seeding onto a pre-existing anal fistula.
  • Carcinoma within a long-standing fistula-in-ano is rare and may be defined by specific neoplastic involvement of the fistulous track in the absence of rectal mucosal carcinoma.
  • The presence of a carcinoma of mucinous histology occurring synchronously in the perianal region and the colon is exceptionally rare.
  • Subsequent clinical follow-up and CT examination of the patient has not revealed recurrent disease at 14 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Mar;39(3):1295-9 [199346.001]
  • [Cites] J R Soc Med. 1992 Jun;85(6):361 [1625275.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):544-5; author reply 545 [14994107.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Dis Colon Rectum. 2003 Jun;46(6):835-6 [12794588.001]
  • [Cites] Chirurg. 2001 May;72(5):573-7 [11383070.001]
  • [Cites] South Med J. 1979 Jun;72(6):764-6 [221988.001]
  • [Cites] Postgrad Med J. 1987 Jun;63(740):503-4 [2829151.001]
  • [Cites] Am J Clin Pathol. 1988 Jun;89(6):809-12 [2835897.001]
  • [Cites] Am J Gastroenterol. 1988 Apr;83(4):460-2 [3348199.001]
  • [Cites] Dis Colon Rectum. 1988 Jan;31(1):68-70 [3366030.001]
  • [Cites] J R Soc Med. 1988 Apr;81(4):217-9 [3373467.001]
  • [Cites] Postgrad Med J. 1987 Mar;63(737):213-4 [3671263.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Am J Proctol. 1970 Apr;21(2):103-12 [4330480.001]
  • [Cites] Rev Esp Enferm Dig. 1995 Apr;87(4):342-3 [7794647.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] JAMA. 1970 Sep 21;213(12):2083 [5468765.001]
  • [Cites] Dis Colon Rectum. 1981 Oct;24(7):562-6 [6271516.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • (PMID = 16961916.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1592294
  •  go-up   go-down


56. Taniguchi M, Ookubo K, Ootsuka M, Akitake H, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Tsujie M, Konishi M, Ebisui C, Fujimoto T: [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2315-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
  • We have experienced a case of successful control of recurrent duodenal carcinoma receiving paclitaxel chemotherapy.
  • A 61-year-old woman with epigastralgia was diagnosed with pyloric gastric carcinoma upon upper gastrointestinal endoscopy and biopsy.
  • So, we additionally resected the anal edge.
  • And 13a, 13b, 12a, p lymph nodes were dissected for duodenal carcinoma.
  • Recurrence of the duodenal carcinoma was diagnosed in February 2007, and S-1 administration was begun.
  • Paclitaxel chemotherapy is effective for duodenal cancer.

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037407.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; EC 2.3.1.21 / Carnitine O-Palmitoyltransferase; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


57. Aydin F, Eisenberger CF, Raffel A, Rehders A, Hosch SB, Knoefel WT: Recurrent Fistula between Ileal Pouch and Vagina-Successful Treatment with a Gracilis Muscle Flap. Case Rep Med; 2009;2009:676392

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent Fistula between Ileal Pouch and Vagina-Successful Treatment with a Gracilis Muscle Flap.
  • Fistulae between an ileal pouch and the vagina are an uncommon complication of ileal pouch-anal anastomosis following proctocolectomy and mucosectomy in patients with familial adenomatous polyposis coli.
  • Several reports describe the successful use of muscle flaps to close recurrent pouch-vaginal-fistulae (PVF).
  • Because local approaches failed, definitive closure of the fistula was achieved by interposition of a gracilis muscle flap between the pouch-anal anastomosis and the vagina.
  • The gracilis muscle flap proved to be an effective method in the treatment of recurrent PVF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tech Coloproctol. 2007 Jun;11(2):128-34 [17510743.001]
  • [Cites] Fam Cancer. 2006;5(3):241-60; discussion 261-2 [16998670.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1316-21 [16752191.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1802-10 [15991061.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1249-53 [15868243.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):241-5 [11167874.001]
  • [Cites] Dis Colon Rectum. 1995 Jan;38(1):4-6 [7813343.001]
  • [Cites] Dis Colon Rectum. 1995 Sep;38(9):921-5 [7656738.001]
  • [Cites] Br J Surg. 1993 Jul;80(7):936-40 [8369945.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):339-53 [15137961.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):911-7 [12847365.001]
  • [Cites] Dis Colon Rectum. 1999 Apr;42(4):486-9 [10215049.001]
  • (PMID = 19718250.001).
  • [ISSN] 1687-9627
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2729290
  •  go-up   go-down


58. Du P: Nonparametric modeling of the gap time in recurrent event data. Lifetime Data Anal; 2009 Jun;15(2):256-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonparametric modeling of the gap time in recurrent event data.
  • Recurrent event data arise in many biomedical and engineering studies when failure events can occur repeatedly over time for each study subject.
  • The proposed technique is demonstrated through an application to the well-known bladder tumor cancer data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123038.001).
  • [ISSN] 1572-9249
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Baysal BE: A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One; 2007 May 09;2(5):e436
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.
  • CONCLUSIONS: The identification of a recurrent, inactivating stop-codon mutation in the SDHB gene in normal blood cells suggests that SDHB is targeted by a cytidine deaminase enzyme.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):180-91 [10485273.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Anal Biochem. 2007 Jan 1;360(1):84-91 [17107651.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):7-10 [17190841.001]
  • [Cites] BMC Biol. 2007;5:12 [17376234.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):715-21 [15649883.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):375-6 [10932175.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):38-50 [11727199.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] Trends Genet. 2003 Apr;19(4):207-16 [12683974.001]
  • [Cites] Annu Rev Genet. 1990;24:305-26 [2088171.001]
  • (PMID = 17487275.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA11236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC1855983
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


60. Kumánovics A, Wittwer CT, Pryor RJ, Augustine NH, Leppert MF, Carey JC, Ochs HD, Wedgwood RJ, Faville RJ Jr, Quie PG, Hill HR: Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases. J Mol Diagn; 2010 Mar;12(2):213-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid molecular analysis of the STAT3 gene in Job syndrome of hyper-IgE and recurrent infectious diseases.

  • Genetic Alliance. consumer health - Hyperimmunoglobulin E recurrent infection syndrome, autosomal dominant.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 2006 Apr;117(4):725-38; quiz 739 [16630926.001]
  • [Cites] Immunol Rev. 2005 Feb;203:244-50 [15661034.001]
  • [Cites] Nat Protoc. 2007;2(1):59-66 [17401339.001]
  • [Cites] J Allergy Clin Immunol. 2007 May;119(5):1234-40 [17335882.001]
  • [Cites] Immunity. 2007 May;26(5):535; author reply 536 [17521577.001]
  • [Cites] Pharmacogenomics. 2007 Jun;8(6):597-608 [17559349.001]
  • [Cites] Nature. 2007 Aug 30;448(7157):1058-62 [17676033.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1608-19 [17881745.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):773-6 [18337720.001]
  • [Cites] Immunol Allergy Clin North Am. 2008 May;28(2):277-91, viii [18424333.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jul;122(1):181-7 [18602572.001]
  • [Cites] J Exp Med. 2008 Jul 7;205(7):1551-7 [18591410.001]
  • [Cites] Mol Immunol. 2008 Nov;46(1):202-6 [18706697.001]
  • [Cites] Hum Mutat. 2009 Jun;30(6):899-909 [19370767.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):853-60 [12765979.001]
  • [Cites] J Pediatr. 2004 Jan;144(1):93-9 [14722525.001]
  • [Cites] Lancet. 1966 May 7;1(7445):1013-5 [4161105.001]
  • [Cites] Pediatrics. 1972 Jan;49(1):59-70 [5059313.001]
  • [Cites] Ann Intern Med. 1975 Jun;82(6):766-71 [1138587.001]
  • [Cites] Cancer. 1977 Jun;39(6):2386-90 [326374.001]
  • [Cites] Anal Biochem. 1997 Feb 15;245(2):154-60 [9056205.001]
  • [Cites] J Pediatr. 1998 Aug;133(2):303-5 [9709729.001]
  • [Cites] N Engl J Med. 1999 Mar 4;340(9):692-702 [10053178.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2521-5 [15621772.001]
  • [Cites] Immunity. 2006 Nov;25(5):745-55 [17088085.001]
  • (PMID = 20093388.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  • [Other-IDs] NLM/ PMC2871728
  •  go-up   go-down


61. Christoforidis D, Cho HM, Dixon MR, Mellgren AF, Madoff RD, Finne CO: Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer. Ann Surg; 2009 May;249(5):776-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery versus conventional transanal excision for patients with early rectal cancer.
  • OBJECTIVE: To compare transanal endoscopic microsurgery (TEMS) with conventional transanal excision (TAE) in terms of the quality of resection, local recurrence, and survival rates in patients with stage I rectal cancer.
  • We excluded patients with node-positive, metastatic, recurrent, previously irradiated, or snare-excised tumors.
  • In the TAE group, 52 (40%) of tumors were <5 cm from the anal verge (AV); in the TEMS group, only 1 (2%) (P = 0.0001).
  • In our multivariate analysis, the tumor distance from the anal verge, the resection margin status, the T stage, and the use of adjuvant therapy--but not the surgical technique (i.e., TEMS or TAE) itself--were independent predictors of local recurrence and DFS.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Patient Selection. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387326.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of rectosigmoid cancer metastasizing to a fistula in ano.
  • We herein report a case of rectosigmoid cancer metastasizing to a fistula in ano.
  • A 53-year-old man complaining of anal bleeding consulted another hospital.
  • He had been suffering from an anal fistula since 7 years.
  • On the left upper side of the skin surface around the anus a fistula end was seen as a hole that tunneled down into the back passage, although no hard tumor was palpable on the hole.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • The anal fistula was a simple type and mucinous discharge was not observed.
  • On 23 February 2004, coring out the anal fistula was performed by the former hospital.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • Recurrent lesions were not seen during the first year after the first operation.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Humans. Lymph Node Excision. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


63. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM, Children's Oncology Group: A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res; 2006 Mar 15;12(6):1750-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
  • PURPOSE: Evaluate the clinical safety, toxicity, immune activation/modulation, and maximal tolerated dose of hu14.18-IL2 (EMD 273063) in pediatric patients with recurrent/refractory neuroblastoma and other GD2-positive solid tumors.
  • EXPERIMENTAL DESIGN: Twenty-seven pediatric patients with recurrent/refractory neuroblastoma and one with melanoma were treated with a humanized anti-GD2 monoclonal antibody linked to human interleukin 2 (IL-2).
  • A phase II clinical trial of hu14.18-IL2, administered at a dose of 12 mg/m2/d x 3 days repeated every 28 days, will be done in pediatric patients with recurrent/refractory neuroblastoma.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4077-85 [11118469.001]
  • [Cites] J Clin Lab Anal. 1996;10(3):160-6 [8731505.001]
  • [Cites] Methods Mol Med. 2003;85:123-31 [12710203.001]
  • [Cites] Nat Rev Immunol. 2003 May;3(5):413-25 [12766763.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jan;53(1):41-52 [14504825.001]
  • [Cites] J Immunother. 2004 May-Jun;27(3):232-9 [15076141.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4839-47 [15269160.001]
  • [Cites] Cancer Res. 1987 Feb 15;47(4):1098-104 [3100030.001]
  • [Cites] J Immunol. 1987 Mar 15;138(6):1992-8 [3493293.001]
  • [Cites] J Immunol. 1987 Jul 1;139(1):285-94 [3108401.001]
  • [Cites] J Clin Invest. 1996 Dec 15;98(12):2801-4 [8981927.001]
  • [Cites] Pain. 1997 Jan;69(1-2):145-51 [9060025.001]
  • [Cites] J Neurol Sci. 1997 Aug;149(2):127-30 [9171318.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):317-33 [9217046.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1706-15 [9473237.001]
  • [Cites] Eur J Nucl Med. 1998 Feb;25(2):144-9 [9473262.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2169-80 [9626218.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1277-88 [9815810.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Mar;6(2):236-42 [10066660.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4463-73 [15483010.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):1951-9 [9816154.001]
  • [Cites] J Natl Cancer Inst. 1988 Nov 16;80(18):1451-61 [3263508.001]
  • [Cites] Biometrics. 1989 Sep;45(3):925-37 [2790129.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5234-9 [2386933.001]
  • [Cites] J Immunother (1991). 1992 Feb;11(2):111-8 [1571333.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):29-37 [8110728.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • (PMID = 16551859.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA032685-23; United States / NCI NIH HHS / CA / R01 CA032685; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCI NIH HHS / CA / P01 CA081403; United States / NCI NIH HHS / CA / P30 CA014520; United States / NCI NIH HHS / CA / R01 CA032685-22A1; United States / NCRR NIH HHS / RR / M01 RR003186-190421; United States / NCI NIH HHS / CA / CA87025; United States / NCRR NIH HHS / RR / RR03186; United States / NCRR NIH HHS / RR / 2M01RR01271; United States / NCRR NIH HHS / RR / M01 RR001271; United States / NCI NIH HHS / CA / CA81403; United States / NCI NIH HHS / CA / CA32685; United States / NCI NIH HHS / CA / CA14520; United States / NCI NIH HHS / CA / R01 CA087025; United States / NCI NIH HHS / CA / R01 CA032685-24
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / EMD 273063 antibody, human; 0 / Interleukin-2
  • [Other-IDs] NLM/ NIHMS73403; NLM/ PMC2587020
  •  go-up   go-down


64. Vanaja DK, Ehrich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ, Cantor CR, Young CY: Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest; 2009 Jun;27(5):549-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of genes for diagnosis and risk stratification of prostate cancer.
  • To identify the relevant CpG sites as molecular markers, for the diagnosis and to distinguish the indolent and aggressive prostate tumors, we have determined the methylation status of 8 genes, including FLNC, EFS, ECRG4, RARB2, PITX2, GSTP1, PDLIM4, and KCNMA1 in 32 nonrecurrent, 32 recurrent primary prostate tumors, and 32 benign prostate tissues using EpiTYPER technology.
  • Specific CpG site hypermethylation of RARB2 and GSTP1 CpG sites were useful for diagnosis of prostate cancer.
  • Furthermore, CpG site hypermethylation of genes FLNC, EFS, ECRG4, PITX2, PDLIM4, and KCNMA1 were associated with prediction of biochemical, local, and systemic recurrence of prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1128-36 [16489065.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10911-8 [17108128.001]
  • [Cites] JAMA. 2006 May 17;295(19):2234-8 [16705097.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3973-8 [16921049.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4236-44 [16896004.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2317-21 [17119066.001]
  • [Cites] Genes Dev. 2006 Dec 1;20(23):3215-31 [17158741.001]
  • [Cites] Eur Urol. 2007 Mar;51(3):665-74; discussion 674 [16956712.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5941-5 [11085508.001]
  • [Cites] J Urol. 2001 Jan;165(1):119-25 [11125379.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1815-26 [11696442.001]
  • [Cites] Urology. 2001 Jun;57(6):1033-7 [11377299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5 [11891299.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):203-9 [12086878.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3376-85 [12177097.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1174-8 [12800218.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1100-9 [12801870.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3877-82 [12873976.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6 [14711987.001]
  • [Cites] J Pathol. 2004 Feb;202(2):233-40 [14743506.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1975-86 [15026333.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1633-8 [15073850.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 May 1;196(3):422-30 [15094313.001]
  • [Cites] Urologe A. 2004 May;43(5):573-9 [15029477.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3935-6 [15217922.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):125-35 [15247353.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 2004 Nov;46(5):660-9; discussion 669 [15474280.001]
  • [Cites] J Mol Biol. 1987 Jul 20;196(2):261-82 [3656447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Feb 1;34(3):549-53 [8621277.001]
  • [Cites] Anal Biochem. 1998 Sep 10;262(2):185-92 [9750131.001]
  • [Cites] Clin Chim Acta. 2004 Dec;350(1-2):181-8 [15530476.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8472-8 [15623627.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):103-15 [15657340.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4037-43 [15930338.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6582-8 [16166436.001]
  • [Cites] J Urol. 2005 Dec;174(6):2191-6 [16280762.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8321-5 [16322291.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):255-61 [16478744.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Cancer J. 2007 Jan-Feb;13(1):17-22 [17464242.001]
  • [Cites] J Urol. 2007 Aug;178(2):459-63; discussion 463 [17561132.001]
  • [Cites] Eur J Cancer. 2007 Jul;43(11):1679-86 [17601725.001]
  • [Cites] J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1 [18289596.001]
  • [Cites] J Urol. 2008 Jun;179(6):2207-10; discussion 2210-1 [18423693.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):659-64 [18692327.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 2):S11-5 [17084157.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):715-7 [16705126.001]
  • (PMID = 19229700.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA091956-080012; United States / NCI NIH HHS / CA / P50 CA091956; United States / NCI NIH HHS / CA / CA091956; United States / NCI NIH HHS / CA / P50 CA091956-080012
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS99244; NLM/ PMC2693083
  •  go-up   go-down


65. Grossman SA, Alavi JB, Supko JG, Carson KA, Priet R, Dorr FA, Grundy JS, Holmlund JT: Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. Neuro Oncol; 2005 Jan;7(1):32-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
  • In this phase 2 study, aprinocarsen was administered to patients with recurrent high-grade gliomas by continuous intravenous infusion (2.0 mg/kg/day for 21 days per month).

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pharmacol. 1996 Aug;50(2):236-42 [8700129.001]
  • [Cites] Glia. 1999 Feb 1;25(3):240-6 [9932870.001]
  • [Cites] J Biopharm Stat. 1997 Mar;7(1):171-8 [9056596.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Biol Chem. 1998 Mar 13;273(11):6001-4 [9497312.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3586-95 [10550158.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3357-63 [10589745.001]
  • [Cites] Prog Neurobiol. 2001 Feb;63(3):321-36 [11115728.001]
  • [Cites] Curr Oncol Rep. 2000 Sep;2(5):445-53 [11122877.001]
  • [Cites] Neurosci Lett. 2001 Jan 19;297(3):163-6 [11137753.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):110-6 [11687282.001]
  • [Cites] Curr Oncol Rep. 2002 Jan;4(1):37-46 [11734112.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40 [11772309.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Feb;72(2):262-5 [11796780.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1042-8 [11948111.001]
  • [Cites] Neurosci Lett. 2002 May 17;324(2):105-8 [11988338.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Aug;283(2):F309-18 [12110515.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2188-92 [12114419.001]
  • [Cites] J Anat. 2002 Jun;200(6):617-27 [12162729.001]
  • [Cites] J Anat. 2002 Jun;200(6):639-46 [12162731.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):96-103 [12672281.001]
  • [Cites] Lancet Neurol. 2003 Jul;2(7):404-9 [12849118.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] J Pharm Sci. 1985 Feb;74(2):229-31 [3989700.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1985 Apr;33(4):1620-32 [4042238.001]
  • [Cites] Biochem Biophys Res Commun. 1987 Oct 29;148(2):718-25 [3689368.001]
  • [Cites] Nature. 1988 Aug 25;334(6184):661-5 [3045562.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Cancer Res. 1989 Jun 15;49(12):3215-7 [2720675.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Sep 29;163(3):1377-83 [2783141.001]
  • [Cites] Cancer Res. 1990 Feb 1;50(3):677-85 [2297708.001]
  • [Cites] Br J Cancer. 1992 Jul;66(1):10-9 [1637658.001]
  • [Cites] Pharmacol Ther. 1993 Sep;59(3):257-80 [8309991.001]
  • [Cites] J Biol Chem. 1994 Jun 10;269(23):16416-24 [7911467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11762-6 [7972137.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;42(2):118-26 [9654111.001]
  • [Cites] Anal Biochem. 1996 Mar 1;235(1):36-43 [8850544.001]
  • (PMID = 15701280.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062475; United States / NCI NIH HHS / CA / U01-CA-26406; United States / NCI NIH HHS / CA / UO1CA-62475
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Phosphorothioate Oligonucleotides; EC 2.7.11.13 / PRKCA protein, human; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-alpha; FMT95051CQ / aprinocarsen
  • [Other-IDs] NLM/ PMC1871621
  •  go-up   go-down


66. Roncucci L: Local recurrences of rectal cancer. Minerva Chir; 2005 Jun;60(3):167-78
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrences of rectal cancer.
  • Data from cancer registries show that incidence of rectal cancer is still high in Italy, while mortality rates are slightly decreasing in most recent years.
  • The rectum may be defined as the tract of the large bowel distal to 12 cm from the anal verge.
  • Pelvic recurrence is evident as a regrowth of cancer in and around the tumor bed.
  • A wide range of recurrence rates after operation for rectal cancer are reported, spanning from 3% to over 30%.
  • This technique has decreased dramatically recurrence rates of rectal cancer, though increasing the risk of local complications.
  • Management of locally recurrent tumors is still unsatisfactory and surgery is feasible only in less than 10% of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985992.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng; ita
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Number-of-references] 80
  •  go-up   go-down


67. Saito N, Suzuki T, Sugito M, Ito M, Kobayashi A, Tanaka T, Kotaka M, Karaki H, Kobatake T, Tsunoda Y, Shiomi A, Yano M, Minagawa N, Nishizawa Y: Bladder-sparing extended resection of locally advanced rectal cancer involving the prostate and seminal vesicles. Surg Today; 2007;37(10):845-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder-sparing extended resection of locally advanced rectal cancer involving the prostate and seminal vesicles.
  • PURPOSE: Total pelvic exenteration (TPE) is the standard procedure for locally advanced rectal cancer involving the prostate and seminal vesicles.
  • METHODS: Eleven patients with advanced primary or recurrent rectal cancer involving the prostate or seminal vesicles, or both, underwent bladder-sparing extended colorectal resection with radical prostatectomy.
  • Local control and urinary and anal function were evaluated postoperatively.
  • Coloanal or colo-anal canal anastomosis was also performed in four patients.
  • CONCLUSION: These bladder-sparing procedures allow conservative surgery to be performed in selected patients with advanced rectal cancer involving the prostate or seminal vesicles, without compromising local control.


68. Cramer DW, Vitonis AF, Welch WR, Terry KL, Goodman A, Rueda BR, Berkowitz RS: Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol; 2010 Dec;119(3):462-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlates of the preoperative level of CA125 at presentation of ovarian cancer.
  • OBJECTIVE: CA125 at presentation of ovarian cancer carries important prognostic significance; but, other than tumor characteristics, little is known about factors that influence CA125 levels.
  • METHODS: CA125 levels before treatment, tumor features, and questionnaire data from 805 women with ovarian cancer receiving care at Partners Hospitals were recorded.
  • For nonmucinous invasive cancers, Jewish ethnicity, parity, prior breast cancer, and family history of breast or ovarian cancer predicted higher CA125, and greater body mass index (BMI), recurrent yeast infections, colitis, and appendectomy predicted lower CA125.
  • In multivariate modeling, stage, ascites, and prior breast cancer were the strongest predictors of high CA125 and appendectomy and yeast infections strongest predictors of low CA125.
  • CONCLUSIONS: Ovarian tumor features and presence of ascites are key determinants of CA125 at diagnosis, but epidemiologic features such as BMI, parity, prior breast cancer, and history of inflammatory conditions of the genitourinary or gastrointestinal tracts may also play a role.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer. 2000 Oct 1;89(7):1555-60 [11013371.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):934-8 [7547243.001]
  • [Cites] Obstet Gynecol. 2002 Jul;100(1):59-64 [12100804.001]
  • [Cites] Int J Gynecol Cancer. 2002 Sep-Oct;12(5):438-42 [12366659.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):77-83 [12468346.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):150-4 [12620910.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Am J Med Sci. 1986 Jul;292(1):25-9 [3521278.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):202-7 [3471274.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):61-7 [2443433.001]
  • [Cites] Gynecol Obstet Invest. 1989;27(3):143-7 [2661359.001]
  • [Cites] Obstet Gynecol. 1990 Sep;76(3 Pt 1):428-31 [2381621.001]
  • [Cites] Obstet Gynecol. 1992 Jun;79(6):1002-10 [1579296.001]
  • [Cites] Gynecol Oncol. 1992 Oct;47(1):87-92 [1427408.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):42-7 [7789889.001]
  • [Cites] J Reprod Med. 1996 Mar;41(3):140-2 [8778409.001]
  • [Cites] Genomics. 1996 Dec 15;38(3):305-13 [8975707.001]
  • [Cites] Acta Oncol. 1997;36(7):755-9 [9490096.001]
  • [Cites] Cancer. 1999 May 1;85(9):2068-72 [10223249.001]
  • [Cites] Hum Reprod Update. 1995 Mar;1(2):173-87 [15726771.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):30-5 [17220329.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):508-15 [17113137.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1383-9 [17416858.001]
  • [Cites] Biol Reprod. 2008 Jan;78(1):134-42 [17942799.001]
  • [Cites] Gynecol Oncol. 2008 Sep;110(3):383-9 [18586313.001]
  • [Cites] J Clin Lab Anal. 2009;23(4):244-8 [19623645.001]
  • [Cites] Int J Gynecol Cancer. 2009 Nov;19(8):1335-8 [20009886.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93 [11352859.001]
  • (PMID = 20850174.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA105009-05; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / U01 CA086381-10; United States / NCI NIH HHS / CA / R01 CA54419; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / R01 CA054419; United States / NCI NIH HHS / CA / 5U01 CA86381; United States / NCI NIH HHS / CA / R01 CA054419-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ NIHMS238531; NLM/ PMC2980911
  •  go-up   go-down


69. Goodison S, Rosser CJ, Urquidi V: Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev Proteomics; 2009 Oct;6(5):507-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary proteomic profiling for diagnostic bladder cancer biomarkers.
  • The ability to detect and monitor bladder cancer in noninvasively obtained urine samples is a major goal.
  • The appropriate use of these approaches has the potential to provide efficient biomarkers for the early detection and monitoring of recurrent bladder cancer.
  • Identification of disease-associated proteins will also advance our knowledge of tumor biology, which, in turn, will enable development of targeted therapeutics aimed at reducing morbidity from bladder cancer.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 1995 Mar 15;154(6):2706-13 [7533181.001]
  • [Cites] Electrophoresis. 1995 Jan;16(1):124-34 [7537657.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):214-23; discussion 224 [8575280.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1690-4 [8603421.001]
  • [Cites] J Urol. 1996 Jun;155(6):2113-9 [8618346.001]
  • [Cites] Electrophoresis. 1996 Jul;17(7):1265-72 [8855415.001]
  • [Cites] J Chromatogr A. 1997 Jul 25;776(1):117-24 [9286085.001]
  • [Cites] J Urol. 1999 May;161(5):1486-9 [10210378.001]
  • [Cites] Int J Cancer. 1999 Sep 24;83(1):18-29 [10449602.001]
  • [Cites] Proteomics. 2004 Nov;4(11):3485-97 [15529407.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1140-9 [15693063.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1729-33 [15765495.001]
  • [Cites] Eur Urol. 2005 Jun;47(6):736-48 [15925067.001]
  • [Cites] Eur Urol. 2005 Jun;47(6):885-93; discussion 893-4 [15925088.001]
  • [Cites] J Urol. 2005 Jul;174(1):64-8 [15947579.001]
  • [Cites] Mass Spectrom Rev. 2005 Nov-Dec;24(6):959-77 [15747373.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):865-71 [15964125.001]
  • [Cites] Proteomics. 2005 Nov;5(16):4296-304 [16196100.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):1920-32 [16127175.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):1917-30 [16335936.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4994-5001 [16281181.001]
  • [Cites] Urology. 2005 Dec;66(6):1256-60 [16360453.001]
  • [Cites] J Proteome Res. 2006 Jan;5(1):183-91 [16396510.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):35-63 [16399415.001]
  • [Cites] Urology. 2005 Dec;66(6 Suppl 1):64-74 [16399416.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):299-305 [16418465.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):432-41 [16428483.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):230-40 [16510332.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):560-2 [16316981.001]
  • [Cites] Urol Oncol. 2006 Mar-Apr;24(2):97-108 [16520271.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1701-7 [16541433.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1760-71 [16837576.001]
  • [Cites] Proteomics. 2006 Oct;6(20):5615-27 [16991199.001]
  • [Cites] J Urol. 2006 Dec;176(6 Pt 1):2347-8 [17085098.001]
  • [Cites] Bioinformatics. 2007 Jan 1;23(1):30-7 [17130137.001]
  • [Cites] Genome Biol. 2006;7(9):R80 [16948836.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D771-9 [17090601.001]
  • [Cites] Eur Urol. 2007 May;51(5):1267-74 [17207912.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1864-74 [17428079.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2631-9 [17518487.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4440-8 [17902641.001]
  • [Cites] Cancer Genomics Proteomics. 2007 Sep-Oct;4(5):329-39 [17993717.001]
  • [Cites] Urology. 2008 Apr;71(4):718-22 [18387400.001]
  • [Cites] Proteomics. 2008 Jun;8(11):2156-9 [18528840.001]
  • [Cites] BMC Cancer. 2008;8:241 [18706098.001]
  • [Cites] J Proteomics. 2008 Oct 7;71(4):490-2 [18620085.001]
  • [Cites] J Proteome Res. 2008 Oct;7(10):4313-25 [18729497.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D907-12 [18978022.001]
  • [Cites] J Am Soc Nephrol. 2009 Feb;20(2):363-79 [19056867.001]
  • [Cites] Anal Chem. 2009 May 15;81(10):3776-83 [19366252.001]
  • [Cites] Prostate. 2009 Jul 1;69(10):1119-27 [19343730.001]
  • [Cites] J Urol. 2009 Jul;182(1):78-84; discussion 84 [19447418.001]
  • [Cites] Lancet. 2009 Jul 18;374(9685):239-49 [19520422.001]
  • [Cites] Clin Cancer Res. 2009 Aug 1;15(15):4935-43 [19602546.001]
  • [Cites] Breast Cancer Res Treat. 2010 Feb;119(3):593-9 [19291396.001]
  • [Cites] Urology. 2000 Jun;55(6):871-5 [10840098.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):634-9 [10953114.001]
  • [Cites] J Urol. 2000 Sep;164(3 Pt 1):680-4 [10954628.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Scand J Urol Nephrol. 2001 Sep;35(4):280-2 [11676352.001]
  • [Cites] Kidney Int. 2002 Oct;62(4):1461-9 [12234320.001]
  • [Cites] J Chromatogr A. 2003 Sep 26;1013(1-2):173-81 [14604118.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):369-73 [14663639.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):323-32 [14675066.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1159-74 [15048996.001]
  • [Cites] Proteomics. 2004 Jul;4(7):1985-8 [15221759.001]
  • [Cites] J Urol. 2004 Sep;172(3):1123-6 [15311054.001]
  • [Cites] Eur Urol. 2004 Oct;46(4):466-71 [15363562.001]
  • [Cites] Urol Clin North Am. 1979 Oct;6(3):599-612 [505675.001]
  • [Cites] J Urol. 1989 Mar;141(3):522-6 [2465418.001]
  • (PMID = 19811072.001).
  • [ISSN] 1744-8387
  • [Journal-full-title] Expert review of proteomics
  • [ISO-abbreviation] Expert Rev Proteomics
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116161
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 74
  • [Other-IDs] NLM/ NIHMS396961; NLM/ PMC3422861
  •  go-up   go-down


70. Nelson RS, Boland E, Ewing BM, Blatchford GJ, Ternent C, Shashidharan M, Tran NA, Beaty J, Thorson AG: Permanent diversion rates after neoadjuvant therapy and coloanal anastomosis for rectal cancer. Am J Surg; 2009 Dec;198(6):765-70
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Permanent diversion rates after neoadjuvant therapy and coloanal anastomosis for rectal cancer.
  • BACKGROUND: The aim of this study was to assess the rate of permanent diversion in patients undergoing coloanal anastomosis after neoadjuvant therapy for rectal cancer.
  • METHODS: We performed a retrospective review of patients with rectal cancer who underwent a total mesorectal excision of a tumor within 9 cm of the anal verge.
  • The average tumor distance from the anal verge was 7 cm (range, 4-9 cm).
  • Twenty-five patients (12%) had recurrent disease, 16 of these were local recurrence.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19969127.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Petrie N, Branagan G, McGuiness C, McGee S, Fuller C, Chave H: Reconstruction of the perineum following anorectal cancer excision. Int J Colorectal Dis; 2009 Jan;24(1):97-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstruction of the perineum following anorectal cancer excision.
  • PURPOSE: Most patients with anal cancer receive chemoradiotherapy as first-line treatment.
  • Persistent/recurrent tumours will subsequently require an abdomino-perineal resection (APR).
  • A proportion of the 20,000 new cases of rectal carcinoma diagnosed in the UK each year receive neo-adjuvant chemoradiation and then an APR.
  • This study investigates a series of 18 patients who underwent APR for anorectal cancer with flap reconstruction of their perineum.
  • RESULTS: Between November 2000 and October 2007, 18 cases were performed (M/F = 7:11), six for anal cancer and 12 for low rectal tumours.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / therapy. Chemotherapy, Adjuvant. Cohort Studies. Female. Humans. Length of Stay. Male. Middle Aged. Neoadjuvant Therapy. Postoperative Complications. Radiotherapy, Adjuvant. Retrospective Studies. Wound Healing

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688618.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Sauer CJ, Klaase JM, Gerritsen JJ, Mastboom WJ: [A malignant tumour in the breast is not always primary breast cancer]. Ned Tijdschr Geneeskd; 2005 Apr 2;149(14):729-34
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A malignant tumour in the breast is not always primary breast cancer].
  • In a 75-year-old woman with a swelling in her left breast, a 39-year-old woman with an anal fissure due to diarrhoea and a 65-year-old woman with chest pain, a mammary tumour was diagnosed that did not originate in mammary tissue.
  • These were a recurrent melanoma, a carcinoma of the thyroid and a B-cell lymphoma, respectively.
  • Breast cancer is one of the most frequently occurring neoplasms in women.
  • Most of these cases concern haematological malignancies and metastases from melanoma and lung cancer.
  • [MeSH-minor] Adult. Aged. Carcinoma / diagnosis. Carcinoma / secondary. Fatal Outcome. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Melanoma / diagnosis. Melanoma / secondary. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2005 Jun 18;149(25):1426; author reply 1426 [15997699.001]
  • (PMID = 15835620.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Mohler JL: A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab; 2008 Apr;22(2):357-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for the androgen-receptor in clinically localized and advanced prostate cancer.
  • Earlier studies of androgen-receptor (AR) expression using frozen prostate tissue, and later studies using archived specimens, produced the consensus that ligand-stabilized AR is nuclear, AR expression is similar in benign epithelia and stroma, AR expression is greater in secretory epithelia than basal cells, and AR expression is more variable in prostate cancer (CaP) than in benign prostatic hyperplasia (BPH).
  • High levels of AR and AR-regulated gene expression indicate a central role for AR in growth regulation of castration-recurrent CaP.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 1999 Jan 1;35(1):2-10 [10554175.001]
  • [Cites] Endocr Relat Cancer. 1999 Dec;6(4):487-502 [10730903.001]
  • [Cites] Cancer. 2000 May 15;88(10):2398-424 [10820364.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):423-7 [11212224.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2892-8 [11306464.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3550-5 [11325816.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4315-9 [11389051.001]
  • [Cites] J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97 [11717329.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):219-26 [11786415.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):34-45 [11900250.001]
  • [Cites] Endocr Relat Cancer. 2002 Mar;9(1):61-73 [11914183.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] Curr Urol Rep. 2002 Feb;3(1):67-74 [12084222.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):3001-15 [12089231.001]
  • [Cites] Eur J Surg Oncol. 2003 Feb;29(1):20-4 [12559071.001]
  • [Cites] J Urol. 2003 Sep;170(3):990-3 [12913756.001]
  • [Cites] J Urol. 2003 Nov;170(5):1817-21 [14532783.001]
  • [Cites] Nat Med. 2004 Jan;10(1):33-9 [14702632.001]
  • [Cites] J Clin Pathol. 2004 Feb;57(2):146-50 [14747438.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):440-8 [14760063.001]
  • [Cites] Comput Methods Programs Biomed. 2004 Jul;75(1):75-9 [15158050.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):928-34 [15223964.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Dec;16(6):400-14 [7536003.001]
  • [Cites] N Engl J Med. 1995 May 25;332(21):1393-8 [7723794.001]
  • [Cites] Nat Genet. 1995 Apr;9(4):401-6 [7795646.001]
  • [Cites] Lab Invest. 1995 Aug;73(2):302-5 [7637331.001]
  • [Cites] Prostate. 1996 Apr;28(4):251-65 [8602401.001]
  • [Cites] J Urol. 1998 Mar;159(3):641-9 [9474117.001]
  • [Cites] J Urol. 1998 Feb;159(2):548-54 [9649289.001]
  • [Cites] Mol Carcinog. 1993;7(3):165-79 [8489712.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1991 Nov-Dec;1(1):21-7 [1845164.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4096-102 [7518349.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • [Cites] Clin Cancer Res. 1996 May;2(5):889-95 [9816246.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):569-76 [10100708.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2511-5 [10363963.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):411-9 [10453285.001]
  • [Cites] Prostate. 2005 Apr 1;63(1):19-28 [15378523.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):309-19 [17045208.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10594-602 [17079484.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8438-43 [17494760.001]
  • [Cites] Prostate. 2008 Jun 1;68(8):830-8 [18324648.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] J Natl Cancer Inst. 1980 Aug;65(2):311-6 [6931251.001]
  • [Cites] J Urol. 1984 Apr;131(4):694-700 [6708184.001]
  • [Cites] Cancer. 1985 Jan 15;55(2):382-8 [2578085.001]
  • [Cites] Cancer. 1986 Jun 15;57(12):2351-6 [2421868.001]
  • [Cites] Science. 1988 Apr 15;240(4850):324-6 [3353726.001]
  • [Cites] Science. 1988 Apr 15;240(4850):327-30 [3353727.001]
  • [Cites] Arch Pathol Lab Med. 1988 Aug;112(8):787-90 [3395214.001]
  • [Cites] Mol Endocrinol. 1988 Dec;2(12):1265-75 [3216866.001]
  • [Cites] J Steroid Biochem. 1989;34(1-6):311-3 [2626023.001]
  • [Cites] J Pathol. 1990 Apr;160(4):329-32 [2193135.001]
  • [Cites] Ann N Y Acad Sci. 1990;595:53-66 [1695829.001]
  • [Cites] Prostate. 1990;17(4):293-300 [1701248.001]
  • [Cites] Int J Cancer. 1991 May 10;48(2):189-93 [1708363.001]
  • [Cites] J Histochem Cytochem. 1991 Jun;39(6):741-8 [1709656.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3057-64 [1710537.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2574-80 [7680949.001]
  • [Cites] J Urol. 1993 May;149(5):1015-9 [7683339.001]
  • (PMID = 18471792.001).
  • [ISSN] 1521-690X
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA077739-100006; United States / NCI NIH HHS / CA / P01 CA077739; United States / NCI NIH HHS / CA / CA 77739; United States / NCI NIH HHS / CA / P01 CA077739-100006
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Receptors, Androgen
  • [Number-of-references] 76
  • [Other-IDs] NLM/ NIHMS52370; NLM/ PMC2799036
  •  go-up   go-down


74. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, Hartmann LC: Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol; 2008 Mar;108(3):619-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Folate receptor alpha as a tumor target in epithelial ovarian cancer.
  • The goal of this study is to improve historical data that lack specific information about FRalpha expression in rare histological subtypes, primary disease versus metastatic foci, and recurrent disease.
  • METHODS: FRalpha expression was analyzed by immunohistochemistry on 186 primary and 27 recurrent ovarian tumors, including 24 pairs of samples obtained from the same individuals at diagnosis and at secondary debulking surgery.
  • RESULTS: FRalpha expression was apparent in 134 of 186 (72%) primary and 22 of 27 (81.5%) recurrent ovarian tumors.
  • In 21 of 24 (87.5%) matched specimens, recurrent tumors reflected the FRalpha status detected at diagnosis.
  • New findings from this study show that FRalpha expression is maintained on metastatic foci and recurrent tumors, suggesting that novel folate-targeted therapies may hold promise for the majority of women with either newly diagnosed or recurrent ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2003 May;44(5):700-7 [12732670.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):52-7 [17582475.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1085-97 [15094208.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Apr 29;56(8):1219-31 [15094217.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Aug;287(2):C517-26 [15102609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5572-6 [2062838.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5329-38 [1717147.001]
  • [Cites] Cancer Res. 1992 Jun 15;52(12):3396-401 [1596899.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5791-6 [8242637.001]
  • [Cites] Cancer. 1994 May 1;73(9):2432-43 [7513252.001]
  • [Cites] Int J Cancer Suppl. 1994;8:89-95 [8194901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9057-61 [7568072.001]
  • [Cites] APMIS. 1995 Sep;103(9):663-70 [7488388.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):121-6 [9583724.001]
  • [Cites] Arch Biochem Biophys. 1999 Jun 15;366(2):183-91 [10356282.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1505-12 [15634643.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Curr Pharm Biotechnol. 2005 Apr;6(2):131-50 [15853692.001]
  • [Cites] J Pharm Sci. 2005 Oct;94(10):2135-46 [16136558.001]
  • [Cites] Front Biosci. 2006;11:506-19 [16146749.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2168-72 [16172227.001]
  • [Cites] Curr Oncol Rep. 2005 Nov;7(6):451-8 [16221382.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Feb;21(1):49-60 [16480331.001]
  • [Cites] Cancer. 2006 May 1;106(9):1933-9 [16572412.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Aug;58(2):229-36 [16331500.001]
  • [Cites] Bioconjug Chem. 2006 May-Jun;17(3):603-9 [16704197.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1994-2004 [16767218.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Sep;33(9):1007-16 [16763819.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4254-61 [16908932.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6170-8 [17062694.001]
  • [Cites] Cancer Immun. 2007;7:6 [17346028.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):141-52 [17333345.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2557-67 [17473184.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):938-42 [17487842.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1585-92 [17551919.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Gene Ther. 2003 Jun;10(12):1018-25 [12776159.001]
  • (PMID = 18222534.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / CA80628; United States / NCI NIH HHS / CA / K12 CA090628-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ NIHMS123756; NLM/ PMC2707764
  •  go-up   go-down


75. Barr E, Sings HL: Prophylactic HPV vaccines: new interventions for cancer control. Vaccine; 2008 Nov 18;26(49):6244-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylactic HPV vaccines: new interventions for cancer control.
  • Human Papillomavirus (HPV) infection causes cervical cancer, a significant portion of anal, vulvar, vaginal, and oropharyngeal cancers, genital warts, and recurrent respiratory papillomatosis (RRP).
  • Planned long-term efficacy and safety evaluations, as well as programs to evaluate vaccine impact on oropharyngeal cancer are also described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18694795.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  • [Number-of-references] 116
  •  go-up   go-down


76. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE: Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol; 2008 Jun;31(3):264-70
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
  • OBJECTIVES: A prospective phase II trial was conducted to evaluate the feasibility, safety, and pathologic response rate of preoperative capecitabine and accelerated synchronous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with locally advanced rectal cancer.
  • At a median follow-up of 26 months (range, 15-40), all patients were alive without evidence of recurrent disease.
  • Of 3 patients who had tumors within 5 cm of the anal verge, 2 underwent sphincter-sparing procedures.
  • CONCLUSIONS: Preoperative chemoradiation with capecitabine and SIB-IMRT is well tolerated and results in an encouraging pCR rate for patients with locally advanced rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525306.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Deng X, Liu H, Huang J, Cheng L, Keller ET, Parsons SJ, Hu CD: Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res; 2008 Dec 1;68(23):9663-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.
  • Radiation therapy is a first-line treatment for prostate cancer patients with localized tumors.
  • Although some patients respond well to the treatment, approximately 10% of low-risk and up to 60% of high-risk prostate cancer patients experience recurrent tumors.
  • Here we show that fractionated ionizing radiation (IR) induces differentiation of LNCaP prostate cancer cells into neuroendocrine (NE)-like cells, which are known to be implicated in prostate cancer progression, androgen-independent growth, and poor prognosis.
  • These results suggest that radiation therapy-induced NE-like differentiation may represent a novel pathway by which prostate cancer cells survive the treatment and contribute to tumor recurrence.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1987 Jul 9-15;328(6126):175-8 [2885756.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7156-68 [15466214.001]
  • [Cites] EMBO J. 1989 Jul;8(7):2023-8 [2529117.001]
  • [Cites] Genes Dev. 1989 Dec;3(12B):2083-90 [2516827.001]
  • [Cites] Oncogene. 1991 Nov;6(11):2019-26 [1658708.001]
  • [Cites] Curr Opin Genet Dev. 1992 Apr;2(2):199-204 [1386267.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):1967-70 [8481896.001]
  • [Cites] Endocrinology. 1998 Mar;139(3):1184-96 [9492053.001]
  • [Cites] Urology. 1998 Apr;51(4):585-9 [9586611.001]
  • [Cites] Exp Cell Res. 1998 Aug 1;242(2):540-7 [9683540.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3821-30 [10447001.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2004;14(4):287-300 [15663358.001]
  • [Cites] J Mol Endocrinol. 2005 Feb;34(1):107-18 [15691881.001]
  • [Cites] Anal Chem. 2005 Mar 1;77(5):1295-302 [15732910.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jul;131(7):407-19 [15887028.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5263-71 [15958572.001]
  • [Cites] J Pathol. 2006 Feb;208(3):401-7 [16369914.001]
  • [Cites] EMBO J. 2006 Mar 8;25(5):1058-69 [16511568.001]
  • [Cites] Endocr Relat Cancer. 2006 Mar;13(1):151-67 [16601285.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10188-95 [16452470.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 May;26(5):1036-42 [16497991.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):523-33 [16820098.001]
  • [Cites] Front Biosci. 2007;12:1814-32 [17127423.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(1):6-14 [17075603.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1405-16 [17685384.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):531-47 [17914087.001]
  • [Cites] BJU Int. 2008 Mar;101 Suppl 2:11-5 [18307687.001]
  • [Cites] Biochim Biophys Acta. 2007 Feb;1769(2):79-91 [17337306.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3663-72 [17440078.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Jun;29(3):128-38 [17672372.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1008-20 [10629058.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):186-95 [10639189.001]
  • [Cites] Annu Rev Biochem. 1999;68:821-61 [10872467.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609 [11483993.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S135-40 [11762341.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S141-4 [11762342.001]
  • [Cites] Cell. 2002 Mar 8;108(5):689-703 [11893339.001]
  • [Cites] Prostate. 2002 May 1;51(2):117-25 [11948966.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] J Neurobiol. 2003 Apr;55(1):14-24 [12605455.001]
  • [Cites] Exp Cell Res. 2003 Aug 1;288(1):198-207 [12878171.001]
  • [Cites] Mol Endocrinol. 2003 Sep;17(9):1726-37 [12775765.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6704-16 [14555984.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] J Cell Physiol. 2004 Mar;198(3):428-40 [14755548.001]
  • [Cites] Cell Death Differ. 2004 Mar;11(3):321-30 [14685164.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5489-95 [15289359.001]
  • [Cites] J Neurosci. 1988 Apr;8(4):1425-35 [3282037.001]
  • (PMID = 19047143.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023168-26S1; United States / NCI NIH HHS / CA / CA023168-28S1; United States / NCI NIH HHS / CA / P30 CA023168-28; United States / NCI NIH HHS / CA / P30 CA023168-26; United States / NCI NIH HHS / CA / CA023168-27S1; United States / NCI NIH HHS / CA / CA023168-27; United States / NCI NIH HHS / CA / P30 CA023168-28S1; United States / NCI NIH HHS / CA / P30 CA023168-27S1; United States / NCI NIH HHS / CA / P30 CA023168-27; United States / NCI NIH HHS / CA / P30 CA023168-25; United States / NCI NIH HHS / CA / P30 CA023168-24; United States / NCI NIH HHS / CA / CCSG CA23168; United States / NCI NIH HHS / CA / P30 CA023168
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATF2 protein, human; 0 / Activating Transcription Factor 2; 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein
  • [Other-IDs] NLM/ NIHMS289051; NLM/ PMC3100895
  •  go-up   go-down


78. Pasetto LM, Basso U, Sinigaglia G, Pucciarelli S, Friso ML, Rugge M, Toppan P, Agostini M, Monfardini S: Rectal cancer adjuvant chemotherapy: when is more useful? Anticancer Res; 2008 May-Jun;28(3B):1805-12
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal cancer adjuvant chemotherapy: when is more useful?
  • THE AIM of the study was to evaluate time-to-progression (TTP) of rectal cancer in a group of patients receiving adjuvant chemotherapy (CHT) after combined neoadjuvant treatment.
  • PATIENTS AND METHODS: From January 2000 to December 2005, 101 consecutive rectal cancer patients who had been neoadjuvantly treated and had underne adjuvant CHT were retrospectively examined.
  • Forty-two patients had a lower (< or =5 cm from the anal verge), 54 a middle (from 6 to 10 cm) and 5 a higher (=10 cm) rectal lesion.
  • Out of locally recurrent patients, 77.8% were N+ (p=0.0026) at the pathological evaluation.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630464.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


79. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, Gerald WL, Powers S, Mu D: Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci U S A; 2007 Oct 16;104(42):16663-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.
  • We used high-resolution array analysis to discover a recurrent lung cancer amplicon located at 14q13.3.
  • Low-level gain of this region was detected in 15% of lung cancer samples, and high-level amplification was detected in an additional 4% of samples.
  • All three genes were overexpressed to varying degrees in amplified samples, although TTF1/NKX2-1 was not expressed in the squamous cancer subtype, consistent with previous reports.
  • Analysis of human lung cancer cell lines by both RNAi and ectopic overexpression further substantiates an oncogenic role for these transcription factors.
  • These results, taken together with previous reports of oncogenic alterations of transcription factors involved in lung development (p63, CEBPA), suggest genetic alterations that directly interfere with transcriptional networks normally regulating lung development may be a more common feature of lung cancer than previously realized.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):512-7 [8814700.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6007-11 [17616654.001]
  • [Cites] J Clin Pathol. 1997 Jan;50(1):30-2 [9059352.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):695-700 [10374779.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):861-7 [15705884.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5561-70 [15994928.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Nat Biotechnol. 2005 Aug;23(8):995-1001 [16025102.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1289-95 [16200064.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1281-8 [16200065.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D153-7 [16381835.001]
  • [Cites] Mod Pathol. 1996 Apr;9(4):445-52 [8729987.001]
  • [Cites] Adv Anat Pathol. 2000 Mar;7(2):123-7 [10721419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 [10805802.001]
  • [Cites] Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13 [11479891.001]
  • [Cites] Cell Tissue Res. 2001 Oct;306(1):57-63 [11683182.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):528-34 [11809705.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Science. 2002 Jul 5;297(5578):63-4 [12098689.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12963-8 [12297621.001]
  • [Cites] Genes Dev. 2002 Oct 15;16(20):2699-712 [12381668.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):297-302 [12676587.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35574-83 [12829717.001]
  • [Cites] Genome Res. 2003 Oct;13(10):2291-305 [12975311.001]
  • [Cites] Science. 2004 Jul 23;305(5683):525-8 [15273396.001]
  • [Cites] Differentiation. 1988 Jun;38(1):60-6 [2846394.001]
  • [Cites] Anal Biochem. 1991 Oct;198(1):80-5 [1724119.001]
  • [Cites] Genes Dev. 1992 May;6(5):691-704 [1577267.001]
  • [Cites] Genes Dev. 1992 Dec;6(12A):2235-47 [1459449.001]
  • [Cites] Genes Dev. 1992 Dec;6(12A):2248-57 [1459450.001]
  • [Cites] Genes Dev. 1996 Jan 1;10(1):60-9 [8557195.001]
  • [Cites] Hybridoma. 1996 Feb;15(1):49-53 [9064286.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):52-62 [16397527.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2005;Suppl 51:OL785-99 [16405855.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):79-89 [16288831.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1556-64 [16187286.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):761-9 [16708353.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Genome Res. 2006 Dec;16(12):1465-79 [17142309.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11632-43 [17178857.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1943-9 [17332321.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3074-84 [17409414.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):E12 [18268316.001]
  • (PMID = 17925434.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA045508; United States / NCI NIH HHS / CA / 5P30CA45508
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / NKX2-8 protein, human; 0 / PAX9 Transcription Factor; 0 / PAX9 protein, human; 0 / TTF1 protein, human; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2034240
  •  go-up   go-down


80. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • 9 patients suffered from a recurrent tumour.
  • After a mean follow up of 44 months (r.: 18-84) 8 patients had deceased for recurrent disease, 15 were alive with a disease progression (2 pelvic recurrences and 13 pure distant deposits) and 24 were alive, without disease.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


81. Meany HJ, Sackett DL, Maris JM, Ward Y, Krivoshik A, Cohn SL, Steinberg SM, Balis FM, Fox E: Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. Pediatr Blood Cancer; 2010 Jan;54(1):47-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • [Cites] J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 [2041050.001]
  • [Cites] J Electron Microsc Tech. 1991 May;18(1):2-10 [2056348.001]
  • [Cites] Bull Assoc Anat (Nancy). 1991 Jun;75(229):105-8 [1777694.001]
  • [Cites] Anal Chem. 2002 Nov 15;74(22):5748-53 [12463358.001]
  • [Cites] Assay Drug Dev Technol. 2004 Aug;2(4):363-72 [15357917.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350-4 [388439.001]
  • [Cites] Anal Biochem. 1983 May;131(1):1-15 [6193725.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):571-9 [3733880.001]
  • [Cites] EMBO J. 1987 Sep;6(9):2597-606 [3315650.001]
  • [Cites] J Cell Biol. 1987 Nov;105(5):2167-77 [3316248.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):206-8 [2757196.001]
  • [Cites] Mol Neurobiol. 1988 Summer;2(2):133-53 [3077315.001]
  • [Cites] J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12 [2359136.001]
  • [Cites] J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8 [2359137.001]
  • [Cites] Cell Mol Life Sci. 1999 Oct 1;56(1-2):133-42 [11213253.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(2):179-84 [11269745.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2090-106 [11932914.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1111-5 [18281544.001]
  • [Cites] Eur J Cancer. 1993;29A(3):395-9 [8398340.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1702-6 [8137285.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3208-13 [9242451.001]
  • [Cites] Jpn J Cancer Res. 1998 Sep;89(9):954-62 [9818032.001]
  • [Cites] Methods Enzymol. 1999;307:173-89 [10506974.001]
  • [Cites] J Med Chem. 1999 Sep 23;42(19):3789-99 [10508428.001]
  • [Cites] Chem Res Toxicol. 2005 Feb;18(2):154-61 [15720119.001]
  • [Cites] J Biomol Screen. 2005 Dec;10(8):795-805 [16234347.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4882-7 [16914576.001]
  • [Cites] Invest New Drugs. 2007 Aug;25(4):285-95 [17384918.001]
  • (PMID = 19731320.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006880-30
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT751; 0 / Sulfonamides; 0 / Tubulin; 0 / Tubulin Modulators
  • [Other-IDs] NLM/ NIHMS144379; NLM/ PMC2783914
  •  go-up   go-down


82. Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolić L: Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics; 2009 Jun;8(6):1278-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.
  • Tamoxifen resistance is a major cause of death in patients with recurrent breast cancer.
  • In the present study we intended to identify putative protein biomarkers indicative of tamoxifen therapy resistance in breast cancer using nano-LC coupled with FTICR MS.
  • ENPP1, EIF3E, and GNB4 were significantly associated with progression-free survival upon tamoxifen treatment for recurrent disease.
  • In summary, comparative proteomics performed on laser capture microdissection-derived breast tumor cells using nano-LC-FTICR MS technology revealed a set of putative biomarkers associated with tamoxifen therapy resistance in recurrent breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2397-403 [16335993.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Oncogene. 2006 Mar 2;25(9):1413-9 [16261164.001]
  • [Cites] Proteomics. 2006 Mar;6(6):1989-2002 [16470630.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1665-71 [16505412.001]
  • [Cites] Electrophoresis. 2006 May;27(9):1840-52 [16645950.001]
  • [Cites] Proteomics. 2006 May;6(9):2903-15 [16596714.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2261-7 [16636340.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1800-10 [16721788.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2194-206 [16944931.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(20):3039-55 [16986208.001]
  • [Cites] Anal Chem. 2006 Nov 1;78(21):7397-409 [17073405.001]
  • [Cites] Anal Chem. 2006 Nov 15;78(22):7796-801 [17105173.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17384-9 [17090686.001]
  • [Cites] Proteomics. 2006 Nov;6(22):5973-82 [17051647.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):9-15 [17210677.001]
  • [Cites] Proteomics. 2007 Jan;7(2):323-9 [17163580.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S15-24 [17259554.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12707-16 [17324924.001]
  • [Cites] Int J Oncol. 2007 Jun;30(6):1545-51 [17487377.001]
  • [Cites] J Biomed Sci. 2007 May;14(3):395-405 [17385060.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1027-34 [17459053.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):403-9 [17563456.001]
  • [Cites] J Am Soc Mass Spectrom. 2007 Jul;18(7):1332-43 [17531500.001]
  • [Cites] Mol Cell Proteomics. 2007 Jul;6(7):1147-57 [17360931.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4407-14 [17671123.001]
  • [Cites] Bioinformatics. 2007 Aug 1;23(15):2021-3 [17545182.001]
  • [Cites] Breast Cancer Res. 2007;9(4):R42 [17626637.001]
  • [Cites] Oncol Res. 2007;16(11):497-506 [18306929.001]
  • [Cites] Eur J Surg Oncol. 2008 Apr;34(4):357-64 [17566693.001]
  • [Cites] Bioinformatics. 2008 Apr 1;24(7):1021-3 [18304935.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1500-7 [18386930.001]
  • [Cites] Breast Cancer Res. 2008;10(2):106 [18430260.001]
  • [Cites] Curr Cancer Drug Targets. 2008 Jun;8(4):243-52 [18537548.001]
  • [Cites] Obesity (Silver Spring). 2008 Jul;16(7):1708-13 [18464750.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2188-94 [18711698.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 17;97(16):1180-4 [16106022.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Anal Chem. 1999 Aug 1;71(15):2957-64 [10450147.001]
  • [Cites] Biotechniques. 2004 Oct;37(4):621-4, 626-33, 636 passim [15517975.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):732-40 [15681518.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Mol Cancer Res. 2005 May;3(5):287-96 [15886300.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):674-89 [15952714.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2680-8 [15892168.001]
  • [Cites] Electrophoresis. 2000 Jun;21(11):2235-42 [10892734.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cell Biol Toxicol. 2000;16(4):207-19 [11101003.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):175-9 [11115556.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):1921-8 [11395366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Lancet. 2002 Oct 12;360(9340):1155-62 [12387968.001]
  • [Cites] Anal Chem. 2003 Mar 1;75(5):1039-48 [12641221.001]
  • [Cites] Proteomics. 2003 Jun;3(6):1037-46 [12833528.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7316-39 [14576841.001]
  • [Cites] Anal Chem. 2004 Jan 1;76(1):144-54 [14697044.001]
  • [Cites] J Proteome Res. 2004 Jan-Feb;3(1):68-75 [14998165.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3422-8 [15161697.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):1063-8 [15473696.001]
  • [Cites] Cancer. 1977 Mar;39(3):1289-94 [912660.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Nov;10(2):105-9 [16358817.001]
  • (PMID = 19329653.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P41 RR018522; United States / NCRR NIH HHS / RR / RR18522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 094ZI81Y45 / Tamoxifen; EC 3.4.21.4 / Trypsin
  • [Other-IDs] NLM/ PMC2690491
  •  go-up   go-down


83. Stipa F, Burza A, Lucandri G, Ferri M, Pigazzi A, Ziparo V, Casula G, Stipa S: Outcomes for early rectal cancer managed with transanal endoscopic microsurgery: a 5-year follow-up study. Surg Endosc; 2006 Apr;20(4):541-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes for early rectal cancer managed with transanal endoscopic microsurgery: a 5-year follow-up study.
  • BACKGROUND: This study aimed to evaluate the long-term risk of local and distant recurrence as well as the survival of patients with early rectal cancer treated using transanal endoscopic microsurgery (TEM).
  • METHODS: The study reviewed 69 patients with Tis/T1/T2 rectal cancer treated using full-thickness excision between 1991 and 1999.
  • The overall cancer-related mortality rate was 7.2%.
  • CONCLUSIONS: After local excision of early rectal cancer, a substantial local recurrence rate is observed.
  • Patients with recurrent Tis/T1 cancers who undergo a salvage operation may achieve good long-term outcome.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Postoperative Care. Preoperative Care. Radiotherapy, Adjuvant. Reoperation. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508812.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


84. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol; 2010 Sep;177(3):1087-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
  • Amplification of the Notch3 locus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant type of ovarian cancer.
  • We have previously demonstrated that ovarian cancer cells, which amplified and overexpressed Notch3, were dependent on Notch3 signaling for cellular survival and growth.
  • In this study, we provide new evidence that Notch3 expression is associated with recurrent postchemotherapy HGSCs.
  • Moreover, patients with recurrent HGSCs in effusion with high Notch3 expression had a significantly worse clinical outcome, including reduced overall survival and shortened progression-free survival than did patients with low Notch3 expressing HGSC.
  • Ectopic expression of the Notch3 intracellular domain led to an increase in IC(50) for carboplatin in an ovarian surface epithelial cell line and in a low-grade serous carcinoma cell line that expressed undetectable levels of Notch3.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2009 May 7;28(18):1941-8 [19305429.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] PLoS One. 2010;5(6):e11198 [20585448.001]
  • [Cites] Anal Cell Pathol. 2001;23(3-4):107-28 [12082292.001]
  • [Cites] Cell. 2003 May 30;113(5):631-42 [12787504.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4144-9 [12874019.001]
  • [Cites] Cancer. 2004 May 15;100(10):2139-47 [15139056.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] J Reprod Med. 1994 Apr;39(4):241-8 [8040839.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):287-95 [15661210.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):487-91 [16186803.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6312-8 [16778208.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):814-9 [16844205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):228-38 [17167759.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):31-44 [17275076.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):749-57 [17429392.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6842-9 [17982121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6326-31 [18436640.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8852-60 [18974129.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1407-15 [19190325.001]
  • [Cites] Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614 [19484149.001]
  • (PMID = 20671266.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA103937; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / R01-CA103937; United States / NCI NIH HHS / CA / R01-CA129080
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH3 protein, human; 0 / Receptors, Notch; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2928943
  •  go-up   go-down


85. Pizzocaro G, Algaba F, Horenblas S, Solsona E, Tana S, Van Der Poel H, Watkin NA, European Association of Urology (EAU) Guidelines Group on Penile Cancer: EAU penile cancer guidelines 2009. Eur Urol; 2010 Jun;57(6):1002-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAU penile cancer guidelines 2009.
  • CONTEXT: Squamous cell carcinoma (SCC) of the penis is a relatively rare but ominous disease.
  • Similarities in etiology with SCC of the head and neck, the female genitalia, and the anal canal have been found.
  • Adjuvant and neoadjuvant chemotherapy showed promising results in patients with advanced or recurrent disease.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / diagnosis. Penile Neoplasms / therapy. Quality of Life / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20163910.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Switzerland
  •  go-up   go-down


86. Ramamoorthy S, Luo L, Luo E, Carethers JM: Tobacco smoking and risk of recurrence for squamous cell cancer of the anus. Cancer Detect Prev; 2008;32(2):116-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tobacco smoking and risk of recurrence for squamous cell cancer of the anus.
  • OBJECTIVE: Squamous cell cancer of the anus is associated with multiple risk factors, including infection with human papillomavirus, immunosuppression, chronic inflammation, and tobacco smoking, although there is little data on these factors for the prediction of recurrent disease.
  • Here, we evaluated the risk of recurrence and mortality of anal carcinoma in association with tobacco smoking.
  • METHODS: We conducted a retrospective review of cases of anal carcinoma from two local hospitals.
  • We obtained information on treatment response and cancer recurrence, as well as tobacco usage from medical records.
  • RESULTS: We identified 64 patients with squamous cell cancer of the anus, and 34 of these (53%) had a tobacco smoking history.
  • Current smokers had higher carcinoma recurrence rates (11/34, 32%) than non-smokers (6/30, 20%).
  • Overall mortality was 33% (21/64), and cancer-related mortality was 23% (15/64).
  • CONCLUSION: Tobacco smoking appears to be associated with anal carcinoma disease recurrence, and is related to increased mortality.
  • This data suggests that patients should be cautioned about tobacco smoking once a diagnosis of anal carcinoma is made in attempt to improve their long-term outcome.

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2337-45 [10590376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):794-800 [17379452.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1544-9 [12697879.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • [Cites] Anesth Analg. 1986 Nov;65(11):1186-8 [3767017.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):159-63 [8417381.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] Am J Prev Med. 1995 Jul-Aug;11(4):245-50 [7495601.001]
  • [Cites] J Gen Virol. 1995 Apr;76 ( Pt 4):1057-62 [9049358.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 21;91(8):708-15 [10218509.001]
  • [Cites] Cancer. 2006 Jun 1;106(11):2428-36 [16634096.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):853-8 [16815535.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31(3):808-12 [11017836.001]
  • (PMID = 18639388.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK067287; United States / NIDDK NIH HHS / DK / R24 DK080506; United States / NIDDK NIH HHS / DK / DK067287-01A2; United States / NIDDK NIH HHS / DK / R24 DK080506-01; United States / NIDDK NIH HHS / DK / R01 DK067287-01A2
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS209533; NLM/ PMC3427794
  •  go-up   go-down


87. Mian C, Lodde M, Comploj E, Lusuardi L, Palermo S, Mian M, Maier K, Pycha A: Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer. J Clin Pathol; 2006 Sep;59(9):984-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer.
  • AIM: To establish independent prognostic factors on a chromosomal basis in superficial bladder cancer, using a multicolour fluorescence in situ hybridisation (FISH) probe mix.
  • PATIENTS AND METHODS: In 2002, voided urine from 75 consecutive patients (mean age 71.7, range 52-93) years under follow-up for superficial urothelial cancer was studied prospectively.
  • 27 of the 74 remaining (36.8%) patients showed recurrent disease.

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2001 Jan;165(1):42-6; discussion 46 [11125360.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Jun;27(3):143-51 [16121635.001]
  • [Cites] Am J Clin Pathol. 2001 Jul;116(1):79-86 [11447756.001]
  • [Cites] BJU Int. 2002 Dec;90(9):846-52 [12460344.001]
  • [Cites] Eur Urol. 2002 Dec;42(6):533-41 [12477647.001]
  • [Cites] J Urol. 2003 Apr;169(4):1291-4 [12629345.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1014-24 [14981102.001]
  • [Cites] Urology. 2004 Mar;63(3):472-5 [15028440.001]
  • [Cites] Eur Urol. 2004 May;45(5):606-12 [15082203.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2367-75 [15160340.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):552-7 [15226775.001]
  • [Cites] J Urol. 1982 Feb;127(2):250-2 [7062375.001]
  • [Cites] J Urol. 1983 Dec;130(6):1083-6 [6644886.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] J Urol. 1991 Jul;146(1):28-31 [2056599.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3807-13 [1676611.001]
  • [Cites] Urology. 1992 Dec;40(6 Suppl):5-10 [1466119.001]
  • [Cites] Am J Pathol. 1993 Nov;143(5):1389-97 [7901994.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):784-8 [8306342.001]
  • [Cites] Hum Mol Genet. 1995 Sep;4(9):1569-77 [8541841.001]
  • [Cites] J Urol. 1997 Apr;157(4):1250-3 [9120913.001]
  • [Cites] J Urol. 1997 Jun;157(6):2116-9 [9146595.001]
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1072-9 [9672255.001]
  • [Cites] Urology. 1999 May;53(5):1005-10 [10223497.001]
  • [Cites] Eur Urol. 2005 Apr;47(4):463-7 [15774242.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):367-71 [15790699.001]
  • [Cites] BJU Int. 2005 Jun;95(9):1219-25 [15892805.001]
  • [Cites] Eur Urol. 2005 Aug;48(2):231-8; discussion 238 [15963635.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):42-55 [11237522.001]
  • (PMID = 16935973.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860484
  •  go-up   go-down


88. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


89. Woloszynska-Read A, Mhawech-Fauceglia P, Yu J, Odunsi K, Karpf AR: Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Clin Cancer Res; 2008 Jun 1;14(11):3283-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer.
  • PURPOSE: The cancer/germline antigen NY-ESO-1 is variably expressed in epithelial ovarian cancer (EOC), with most tumors showing low or heterogeneous expression, which limits patient responses to NY-ESO-1 vaccine therapy.
  • These findings support a novel chemoimmunotherapy approach using decitabine to augment NY-ESO-1 vaccine therapy for treatment of recurrent EOC.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Mol Pharmacol. 2004 Jan;65(1):18-27 [14722233.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4472-80 [15231656.001]
  • [Cites] Immunogenetics. 1995;42(4):282-90 [7672823.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7149-53 [8692960.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1245-52 [9515812.001]
  • [Cites] Cancer J Sci Am. 1999 Jan-Feb;5(1):20-5 [10188057.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7327-35 [10523621.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9167-71 [15604288.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7751-62 [16140943.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7763-74 [16140944.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10118-26 [16497664.001]
  • [Cites] Mol Cancer Res. 2006 May;4(5):339-49 [16687489.001]
  • [Cites] Adv Cancer Res. 2006;95:1-30 [16860654.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5777-85 [17020984.001]
  • [Cites] Oncogene. 2006 Nov 2;25(52):6975-85 [16715135.001]
  • [Cites] Cell. 2007 Feb 23;128(4):683-92 [17320506.001]
  • [Cites] Histol Histopathol. 2007 Sep;22(9):1005-15 [17523078.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4394-403 [17260018.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42 [17652518.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5553-63 [17353906.001]
  • [Cites] Epigenetics. 2006 Jul-Sep;1(3):116-20 [17786175.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):777-84 [17957795.001]
  • [Cites] Cancer Immun. 2007;7:21 [18095639.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):146-50 [12866414.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6076-83 [14522938.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6484-8 [14528272.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • (PMID = 18519754.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA116674; United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R01 CA116674-02; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / R01CA11674; United States / NCI NIH HHS / CA / CA116674-04; United States / NCI NIH HHS / CA / CA116674-01A1; United States / NCI NIH HHS / CA / CA116674-02; United States / NCI NIH HHS / CA / R01 CA116674-03; United States / NCI NIH HHS / CA / R01 CA116674-01A1; United States / NCI NIH HHS / CA / R01 CA116674-04; United States / NCI NIH HHS / CA / 5T32CA009072; United States / NCI NIH HHS / CA / T32 CA009072; United States / NCI NIH HHS / CA / CA116674-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Membrane Proteins
  • [Other-IDs] NLM/ NIHMS182570; NLM/ PMC2835568
  •  go-up   go-down


90. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, Steup WH, Wiggers T, Rutten HJ, Marijnen CA: Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study. J Clin Oncol; 2005 Sep 1;23(25):6199-206
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients--a Dutch colorectal cancer group study.
  • Also, hospital treatment was recorded for diseases possibly related to late side effects of rectal cancer treatment.
  • PATIENTS AND METHODS: Long-term morbidity was assessed in patients from the prospective randomized TME trial, which investigated the efficacy of 5 x 5 Gy before TME surgery for mobile rectal cancer.
  • Dutch patients without recurrent disease were sent a questionnaire.
  • However, irradiated patients, compared with nonirradiated patients, reported increased rates of fecal incontinence (62% v 38%, respectively; P < .001), pad wearing as a result of incontinence (56% v 33%, respectively; P < .001), anal blood loss (11% v 3%, respectively; P = .004), and mucus loss (27% v 15%, respectively; P = .005).
  • CONCLUSION: Although preoperative short-term radiotherapy for rectal cancer results in increased local control, there is more long-term bowel dysfunction in irradiated patients than in patients who undergo TME alone.
  • Rectal cancer patients should be informed on late morbidity of both radiotherapy and TME.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16135487.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Sakakura C, Nishio M, Miyagawa K, Miyashita A, Nagata H, Kin S, Fukuda K, Nakase Y, Hagiwara A, Nakanishi M, Yamazaki J, Yoshikawa S, Okamoto K, Kokuba Y, Otsuji E: Laparoscope-assisted superlow anterior resection combined with inter sphincteric rectal dissection for very low advanced rectal cancers combined with preoperative chemotherapy. Hepatogastroenterology; 2009 May-Jun;56(91-92):692-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal intersphincteric resection (ISR) has been increasingly used as a surgical treatment for extremely low rectal cancer.
  • The patient was a 46-year-old male with advanced rectal cancer on the lower rectum adjacent to the dentate line.
  • This patient showed favorable recovery including postoperative anal function with no complications or recurrent disease.
  • This procedure is feasible and has favorable short-term results for the radical treatment of very low rectal disease, while preserving anal function.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Antineoplastic Agents / therapeutic use. Dissection / methods. Laparoscopy. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621682.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


92. Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer; 2005;5:133
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients.
  • A truncated form of TTR has recently been described to be part of a set of biomarkers for the diagnosis of ovarian cancer.
  • The main aim of the study was therefore to characterize differences in microheterogeneity between ascitic fluid and plasma of women affected with ovarian cancer and to evaluate the tumor site as the possible source of TTR.
  • METHODS: Subjects were 48 women with primary invasive epithelial ovarian cancer or recurrent ovarian carcinoma.
  • CONCLUSION: The severity of the cancer associated catabolism as well as the inflammation status affect serum TTR and RBP levels.
  • [MeSH-minor] Adult. Aged. C-Reactive Protein / biosynthesis. Carcinoma / blood. Carcinoma / metabolism. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation. Inflammation. Middle Aged. Peroxidases / metabolism. Recurrence. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Obstet Gynecol. 2000 Feb;12(1):39-42 [10752515.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 May;4(1):7-15 [15975260.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 3:141-4 [11079131.001]
  • [Cites] Arch Intern Med. 2001 Dec 10-24;161(22):2733-7 [11732940.001]
  • [Cites] Anal Biochem. 2002 Feb 1;301(1):49-56 [11811966.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Muscle Nerve. 2002 Sep;26(3):417-20 [12210373.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1281-91 [12553432.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1320-4 [12553437.001]
  • [Cites] Clin Chem Lab Med. 2002 Dec;40(12):1344-8 [12553442.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):191-7 [12716133.001]
  • [Cites] Hum Reprod. 2003 Jun;18(6):1259-64 [12773456.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 10;310(1):242-6 [14511677.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49707-13 [14507924.001]
  • [Cites] Nutr Cancer. 2003;46(2):148-57 [14690790.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):337-45 [14695346.001]
  • [Cites] Int J Vitam Nutr Res. 2003 Nov;73(6):423-30 [14743546.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1223-9 [15154651.001]
  • [Cites] J Obstet Gynaecol Can. 2004 Aug;26(8):717-28 [15307976.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Zentralbl Gynakol. 2004 Oct;126(5):315-22 [15478050.001]
  • [Cites] Ann Nutr Metab. 2004;48(4):241-5 [15331882.001]
  • [Cites] Curr Oncol Rep. 2004 Nov;6(6):456-62 [15485615.001]
  • [Cites] J Clin Pathol. 1991 Jul;44(7):573-5 [1713221.001]
  • [Cites] Sci China B. 1991 Nov;34(11):1312-8 [1666289.001]
  • [Cites] Gynecol Obstet Invest. 1994;37(2):135-40 [8150370.001]
  • [Cites] Nutr Rev. 1994 Feb;52(2 Pt 2):S13-23 [8202278.001]
  • [Cites] Annu Rev Nutr. 1994;14:495-533 [7946531.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11 Suppl):135-9 [8608044.001]
  • [Cites] Neurosci Lett. 1997 Dec 5;238(3):123-6 [9464635.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Aug 10;249(1):26-30 [9705825.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Gen Comp Endocrinol. 2000 Sep;119(3):241-55 [11017772.001]
  • (PMID = 16225703.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Prealbumin; 9007-41-4 / C-Reactive Protein; EC 1.11.1.- / Peroxidases
  • [Other-IDs] NLM/ PMC1274304
  •  go-up   go-down


93. Yu J, Zhang C, Wang YN, Hu YF, Cheng X, Li GX: [Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov;12(6):573-6
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic versus open total mesorectal excision for the middle-lower rectal cancer: a clinical comparative study].
  • OBJECTIVE: To evaluate the feasibility, safety, radicality and short-term outcome of laparoscopic total mesorectal excision(TME) in comparison with open procedure for the middle-lower rectal cancer.
  • METHODS: From November 2005 to October 2008, 93 patients with middle-lower rectal cancer received laparoscopic total mesorectal excision (LTME group), while 105 patients underwent conventional open TME (OTME group).
  • The anal sphincter preserved procedure accounted for 82.8% in LTME group and 81.9% in OTME group.
  • The recurrent rate and overall survival rate were 4.4% and 97.8% in LTME group, with no significant difference compared to those in OTME group (7.3% and 97.9%, P >0.05).
  • CONCLUSIONS: Laparoscopic TME for middle-low rectal cancer is safe and feasible, and can potentially offer all the benefits of a minimally invasive approach and achieve satisfactory oncological outcome,which may lead to a better future of the TME technique.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19921566.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


94. Li HX, Li M, Li CL, Ma JH, Wang MR, Rao J, Pan QJ: ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol; 2010 Feb;32(1):45-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study.
  • OBJECTIVE: To determine whether ImmunoCyt (uCyt+) immunofluorescence and cytokeratin 20 (CK20) immunocytochemistry add additional diagnostic value in the detection of urothelial carcinoma (UC) in samples of urine liquid-based cytology (LBC).
  • RESULTS: Of 169 inpatients, 135 cases had histologic diagnoses, including 93 cases of UC with primary tumors in 68 and recurrent tumors in 25, 26 cases of other urologic malignancies and 16 cases of benign urologic lesions.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701087.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-20
  •  go-up   go-down


95. Doornebosch PG, Ferenschild FT, de Wilt JH, Dawson I, Tetteroo GW, de Graaf EJ: Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer. Dis Colon Rectum; 2010 Sep;53(9):1234-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrence after transanal endoscopic microsurgery (TEM) for T1 rectal cancer.
  • PURPOSE: The aim of this study was to evaluate the management and outcome of local recurrences after transanal endoscopic microsurgery for T1 rectal cancer.
  • METHODS: Consecutive patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer at a Dutch referral center (IJsselland Hospital) were registered in a prospective database.
  • Follow-up was according to Dutch guidelines on rectal cancer, with additional rigid rectoscopy and endorectal ultrasound examinations every 3 months for the first 2 years, and every 6 months thereafter.
  • RESULTS: Of a total of 88 patients who underwent transanal endoscopic microsurgery for pT1 rectal cancer, 18 patients (20.5%) had a local recurrence.
  • At 3 years, overall survival was 31%; cancer-related survival was 58%.
  • CONCLUSIONS: Recurrent disease after transanal endoscopic microsurgery for T1 rectal cancer is a major problem.
  • [MeSH-minor] Aged. Aged, 80 and over. Anal Canal. Endosonography. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2010 Sep;53(9):1231-3 [20706064.001]
  • (PMID = 20706065.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Mureşan M, Bancu S, Bara T, Bancu L, Turcu M, Mureşan S: [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer]. Chirurgia (Bucur); 2009 Jul-Aug;104(4):415-8
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrence after the sphincter-saving operations and abdominal perineal resection in rectal cancer].
  • By local recurrence we define the appearance of the same anatomopathological type of cancer like the one initially described in the primary tumor, limited at the rectum or pelvis.The study is based on the analysis of all the cases with rectal cancer who undergone surgical procedures in Surgical Clinic No.2 Tg.
  • Using the most important parameters for each patient we identified some risk factors for the recurrence of the rectal cancer: surgical procedures--there were no major variations in the local recurrence between the sphincter-saving operations and abdominal perineal resections.
  • The recurrent rectal cancer is more frequent in aged patients with high aggressive adenocarcinomas.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Anal Canal. Neoplasm Recurrence, Local / surgery. Perineum / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / surgery. Aged. Carcinoma, Squamous Cell / surgery. Digestive System Surgical Procedures / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886048.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


97. Zbar AP, Shenoy RK, Chiappa A: Extended abdominoperineal resection in women: the Barbadian experience. Int Semin Surg Oncol; 2007;4:1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: We report our results of a selective approach to primary direct appositional vaginal repair versus transverse rectus abdominis flap repair (TRAM) in patients with extensive rectal/anal cancer or in cases with primary cancer of cervix, vagina or vulva involving the anal canal and anal sphincters.
  • Exenterative procedures were performed in 2 cases of primary vaginal cancer, following Wertheim hysterectomy for carcinoma of the cervix with recurrence after radiation and in 2 further cases of anal cancer with extensive pelvic recurrence after primary chemoradiation.
  • Fifteen cases are alive on follow-up with no evidence of disease; 2 patients who had recurrent carcinoma of the cervix and who underwent TRAM flap reconstruction, have recurrent disease after 5 and 6 months of follow-up, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2005 May;97(2):596-601 [15863165.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2229-35 [8918419.001]
  • [Cites] Am Surg. 2005 Feb;71(2):117-22 [16022009.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1046 [16034808.001]
  • [Cites] Ann Surg Oncol. 2005 Feb;12(2):104-10 [15827789.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):482-6 [15736219.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):438-43 [15719190.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):476-81; discussion 481-2 [15714245.001]
  • [Cites] Int Urogynecol J Pelvic Floor Dysfunct. 2005 Sep-Oct;16(5):389-94 [15657636.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):398-403 [15297179.001]
  • [Cites] Gynecol Oncol. 2004 Jun;93(3):610-4 [15196852.001]
  • [Cites] World J Gastroenterol. 2004 Feb 1;10(3):424-6 [14760771.001]
  • [Cites] Ann Surg Oncol. 2004 Jan;11(1):27-33 [14699030.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):39-45 [12468340.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1144-50 [12209702.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):239-45; discussion 245-8 [11852339.001]
  • [Cites] Arch Surg. 1990 Oct;125(10):1371-6; discussion 1376-7 [2222178.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Plast Reconstr Surg. 1983 Dec;72(6):751-65 [6647599.001]
  • [Cites] Dis Colon Rectum. 1994 Sep;37(9):890-6 [8076488.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):261-8 [16426668.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):542-8 [15882183.001]
  • (PMID = 17214895.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779795
  •  go-up   go-down


98. Lu W: Marginal regression of multivariate event times based on linear transformation models. Lifetime Data Anal; 2005 Sep;11(3):389-404
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Marginal distributions are specified for the multivariate event times in multiple events and clustered events data, and for the gap times in recurrent events data, using the semiparametric linear transformation models while leaving the dependence structures for related events unspecified.
  • An application to the well-known bladder cancer tumor recurrences data is also given to illustrate the methodology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133886.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Chrysos E, Athanasakis E, Vrekousis T, Almarashdah S, Fiorentini G, Xynos E, Zoras O: Abdominal and pelvic stop-flow chemotherapy. Effect of chemotherapeutic agents and tissue ischemia on rectoanal pressures. J Exp Clin Cancer Res; 2006 Sep;25(3):303-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stationary rectoanal manometry was performed within 24 hrs before and repeated 48 hrs after stop-flow chemotherapy in 7 consecutive patients with a history of locally advanced or recurrent abdominal and pelvic tumors.
  • Anal sphincter resting and squeeze pressures, rectal sensitivity, rectoanal inhibitory reflex and rectal volumes at which temporary and permanent urge to defecate were reported were examined.
  • Intraoperatively, changes in rectal and anal resting pressures before, during and after occlusion of the vessels and after administration of chemotherapeutic agent were as well recorded, analyzed and interpreted using ambulatory manometry.
  • Induction of anesthesia reduced distal and proximal anal resting pressures.
  • Intraoperative administration of chemotherapy did not further affect anal resting pressures during or after hypoxia.
  • Tissue hypoxia induced by vascular occlusion during stop-flow chemotherapy procedure, seems to be the only factor leading to a dramatic drop of anal pressures.
  • Anal pressures fully recover after reperfusion of the isolated area.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Anal Canal / drug effects. Antineoplastic Agents / pharmacokinetics. Chemotherapy, Cancer, Regional Perfusion / methods. Ischemia / pathology. Pelvic Neoplasms / drug therapy. Rectum / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17167968.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


100. Renlund N, Pieretti-Vanmarcke R, O'Neill FH, Zhang L, Donahoe PK, Teixeira J: c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction. Endocrinology; 2008 Jan;149(1):108-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of the MIS type II receptor (MISRII) in ovarian cancer cells and the ability of MIS to inhibit proliferation of these cells suggest that MIS might be a promising therapeutic for recurrent ovarian cancer.
  • Moreover, treatment of mouse ovarian cancer cells with a combination of SP600125 and paclitaxel, an established chemotherapeutic agent used in the treatment of ovarian cancer, or with MIS enabled inhibition of cell proliferation at a lower dose than with each treatment alone.
  • These results offer a strong rationale for testing the therapeutic potential of SP600125, alone or in combination with already established drugs, in the treatment of recurrent ovarian cancer with a much-needed decrease in the toxic side effects of currently employed therapeutic agents.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2001 Oct;22(5):657-74 [11588147.001]
  • [Cites] Nat Cell Biol. 2001 Aug;3(8):708-14 [11483955.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):168-72 [11774260.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jan 5;766(1):89-98 [11820299.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4883-91 [11729207.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2640-6 [12171896.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36024-31 [12130649.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):408-10 [12368913.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1389-97 [12649204.001]
  • [Cites] Oncogene. 2003 Jul 10;22(28):4314-32 [12853969.001]
  • [Cites] Mol Cell Endocrinol. 2003 Dec 15;211(1-2):43-9 [14656475.001]
  • [Cites] Oncogene. 2003 Dec 8;22(56):9075-86 [14663486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15601-6 [14671316.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):259-64 [14573624.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2185-95 [15141161.001]
  • [Cites] J Surg Res. 1977 Aug;23(2):141-8 [886843.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Genes Dev. 1993 Nov;7(11):2135-48 [8224842.001]
  • [Cites] Genes Dev. 1996 Oct 15;10(20):2577-87 [8895659.001]
  • [Cites] Science. 1995 Nov 24;270(5240):1326-31 [7481820.001]
  • [Cites] Cell. 1994 Nov 4;79(3):415-25 [7954809.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1429-32 [8999807.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1677-81 [8999845.001]
  • [Cites] Mol Cell Biol. 1998 Apr;18(4):1844-54 [9528756.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3091-100 [9606191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):111-6 [15618407.001]
  • [Cites] Nat Med. 2005 Jan;11(1):63-70 [15619626.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3219-24 [15728372.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Apr;313(1):325-32 [15626722.001]
  • [Cites] Anal Biochem. 2006 Feb 1;349(1):78-86 [16307714.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2072-81 [16287090.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1593-8 [16533786.001]
  • [Cites] Development. 2006 Jun;133(12):2359-69 [16687449.001]
  • [Cites] J Bone Miner Res. 2006 May;21(5):674-83 [16734382.001]
  • [Cites] J Med Chem. 2006 Jun 15;49(12):3563-80 [16759099.001]
  • [Cites] Oncogene. 2006 Aug 10;25(35):4857-66 [16547493.001]
  • [Cites] Genes Cells. 2006 Sep;11(9):983-92 [16923120.001]
  • [Cites] Mol Endocrinol. 2006 Oct;20(10):2382-91 [16740653.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17426-31 [17088539.001]
  • [Cites] Endocrinology. 1996 Jan;137(1):160-5 [8536608.001]
  • [Cites] EMBO J. 2000 Apr 17;19(8):1745-54 [10775259.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27973-8 [10854429.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28371-9 [10874041.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):936-45 [11376112.001]
  • [Cites] Mol Endocrinol. 2001 Jun;15(6):946-59 [11376113.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6 [11717429.001]
  • (PMID = 17947357.001).
  • [ISSN] 0013-7227
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA017393; United States / NCI NIH HHS / CA / CA17393
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracenes; 0 / Bone Morphogenetic Proteins; 0 / Enzyme Inhibitors; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anthra(1,9-cd)pyrazol-6(2H)-one; 0 / anti-Mullerian hormone receptor; 80497-65-0 / Anti-Mullerian Hormone; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2194615
  •  go-up   go-down






Advertisement